Synthesis of novel 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as selective and potent anti-tumor agents by Karim, Mohammad
Duquesne University
Duquesne Scholarship Collection
Electronic Theses and Dissertations
Spring 5-11-2018
Synthesis of novel 5-substituted
pyrrolo[2,3-d]pyrimidine antifolates as selective
and potent anti-tumor agents
Mohammad Karim
Follow this and additional works at: https://dsc.duq.edu/etd
Part of the Medicinal and Pharmaceutical Chemistry Commons
This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.
Recommended Citation
Karim, M. (2018). Synthesis of novel 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as selective and potent anti-tumor agents
(Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1425
  
SYNTHESIS OF NOVEL 5-SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINE 
ANTIFOLATES AS SELECTIVE AND POTENT ANTI-TUMOR AGENTS 
 
 
  
 
A Thesis 
Submitted to the Graduate School of Pharmaceutical Sciences 
 
 
 
Duquesne University 
 
In partial fulfillment of the requirements for 
the degree of Master of Science 
 
By 
Mohammad Anwarul Karim 
 
May 2018 
 
  
  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Copyright by 
Mohammad Anwarul Karim 
 
2018
 iii 
 
 
 
 
SYNTHESIS OF NOVEL 5-SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINE  
 
ANTIFOLATES AS SELECTIVE AND POTENT ANTI-TUMOR AGENTS 
 
 
 
 
 
 
 
By 
 
Mohammad Anwarul Karim 
 
Approved March 12, 2018 
 
 
________________________________ 
Aleem Gangjee 
Professor of Medicinal Chemistry 
School of Pharmacy Distinguished Professor 
Graduate School of Pharmaceutical Sciences 
Duquesne University 
Pittsburgh, PA 
(Committee Chair) 
________________________________ 
Marc W. Harrold 
Professor of Medicinal Chemistry 
Graduate School of Pharmaceutical Sciences 
Duquesne University 
Pittsburgh, PA 
(Committee Member) 
________________________________ 
Kevin Tidgewell 
Assistant Professor of Medicinal Chemistry 
Graduate School of Pharmaceutical Sciences 
Duquesne University 
Pittsburgh, PA 
(Committee Member) 
 
 
 
 
 
 
 
 
 
 
  
________________________________ 
J. Douglas Bricker  
Dean, School of Pharmacy and the Graduate 
School of Pharmaceutical Sciences 
Duquesne University 
Pittsburgh, PA 
 
 iv 
ABSTRACT 
 
SYNTHESIS OF NOVEL 5-SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINE 
ANTIFOLATES AS SELECTIVE AND POTENT ANTI-TUMOR AGENTS 
 
 
 
By 
Mohammad Anwarul Karim 
May 2018 
 
Dissertation supervised by Professor Aleem Gangjee 
In last few decades many folate analogs have been discovered and several 
compounds are successfully being used as anticancer agents. Methotrexate (MTX), 
pemetrexed (PMX), raltitrexed (RTX): are a few examples of classical antifolates that are 
currently in clinical use. Although these compounds are widely used, all of them show dose 
limiting toxicity due to their non-specific transport into normal cells as well as malignant 
cells. Currently, clinically used classical antifolates suffer from this disadvantage because 
there is no way to selectively transport them into malignant cells. Currently available 
antifolates are transported via reduced folate career (RFC) as well as Folate receptors (FRs) 
and/or Proton coupled folate transporter (PCFT). Because RFC is ubiquitous in the human 
body, the dose limiting toxicity is unavoidable for an antifolate if it is a substrate for RFC. 
 v 
To circumvent this challenge with antifolate chemotherapy, it is necessary to develop 
agents which are selective for the cancerous tissues. Exploiting the site specificity of FRs 
and/or the acidic pH specificity of PCFT, the goal of developing targeted antifolate agents 
could be achieved. This approach of selective transport into tumor cells via FRs and/or 
PCFT and over RFC targets inhibition of GARFTase dependent salvage pathway for purine 
biosynthesis inside the tumor. Based on this premise, five 5-substituted pyrrolo[2,3-
d]pyrimidines have been designed, synthesized and characterized. Among them four are 
novel compounds and one is a previously reported compound. The previously reported 
compound has never been tested for FR/PCFT-GARFTase selectivity before, and therefore 
was of interest and was synthesized.  
 
Figure (abstract). 5-substituted pyrrolo[2,3-d]pyrimidine with variation in the linker 
length and side chain aromatic group. 
To investigate the role of side chain aromatic group in the folate analogs, phenyl, 
fluorophenyl and furan groups have been placed in the linker region. The compounds 
comprise of different aliphatic linker chain length from 2C to 5C. To test selectivity, FR 
and PCFT transport have been studied and GARFTase inhibitory assay will be conducted. 
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I. BIOCHEMICAL REVIEW 
 
Folic acid (FA) is a water soluble vitamin which was first reported nearly eight decades 
ago. The compound was first isolated by Mitchell et al.1 in 1941. Tetrahydrofolate (THF) is a 
reduced derivative of folic acid.  There are three structural segments in folic acid: a scaffold, which 
is a hetero-bicyclic pteridine ring; a linker, which is p-amino benzoic acid (PABA); and a terminal 
portion, glutamic acid (Figure 1). FA also has an alternate name of pteroylglutamic acid. In nature 
FA is not found in its original chemical form, rather several derivatives are found. As such, the 
natural forms of folic acid derivatives are represented by the term folates and the oxidized synthetic 
form that is used in dietary supplements is represented by the term folic acid. There are several 
oxidized and reduced states of folates (oxidized, 7,8-H2, and 5,6,7,8-H4). On N
5 or N10 or on both 
nitrogen atoms of the molecule, one carbon units can be attached. There could also be additional 
glutamate units attached via γ-peptide bonds to yield folate polyglutamates. 
 
 
                                                Figure 1. Folic acid structure1 
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1. Role of folate in biochemical processes 
 
     Figure 2. Folate’s role in nucleic acid and amino acid synthesis1-2  
Folic acid is necessary for DNA synthesis and the metabolic cycle of folic acid plays an 
important role in mammal biochemistry. In the folic acid metabolism cycle, the one carbon transfer 
occurs to amino acids, nucleotides and biomolecules. Intestinal absorption by the proton coupled 
folate transporter (PCFT) is the major mechanism of folic acid absorption. Tetrahydrofolic acid 
(THF) is generated from folic acid. For this generation process, a NADPH (nicotinamide adenine 
dinucleotide phosphate) specific enzyme, dihydrofolate reductase (DHFR), reduces folic acid 
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either partially or fully to yield 7,8-dihydrofolate (DHF) or 5,6,7,8-tetrahydrofolate (THF) 
respectively. Further oxidative enzymatic modification makes THF a one carbon donor. The 
residual dihydrofolate can be converted to tetrahydrofolate. Any compound that can act as an 
inhibitor in any of the steps in folate metabolism is called an antifolate. These antimetabolites have 
chemotherapeutic application potential.  
In intracellular homocysteine remethylation process, 5-MethylTHF acts as a methyl donor. 
Serine hydroxymethyltransferase (SHMT), a vitamin B6-dependent enzyme, converts THF into 
5,10-methyleneTHF. Two isoforms of SHMT have been identified and they utilize serine as a one-
carbon donor. A trifunctional enzyme, methylenetetrahydrofolate dehydrogenase (MTHFD), is 
responsible for converting THF into 5,10-methyleneTHF, via N10-formylTHF and 5,10-
methenylTHF. N10-formylTHF plays a role in the purine biosynthesis pathway as a one carbon 
donor and 5,10-methylene THF plays a role in converting dUMP into dTMP.2 dUMP to dTMP 
conversion is catalyzed by the enzyme thymidylate synthase (TS). TS utilizes 5,10-methyleneTHF 
both as a methyl source and as a reductant.  5,10-MethyleneTHF is converted to dihydrofolate 
(DHF) by simultaneous transfer of a methylene group and the 6-hydrogen atom as hydride. As 
mentioned previously, this DHF could be converted back to THF via the action of DHFR.  
In the de novo purine biosynthesis pathway there are two folate-related enzymes, β-
glycinamide-ribonucleotide transformylase (GARFTase) and aminoimidazolecarboxamide 
ribosyl-5-phosphate formyl transferase (AICARFTase), that transfer a one carbon unit. These two 
enzymes utilizes CHO-THF as the one carbon donor. (Figure 3).3 These transferred one-carbon 
units are the C-8 and C-2 of synthesized purines. The first enzyme, GARFTase, is part of a 
trifunctional protein which is active in the second, third and fifth step of purine biosynthesis 
pathway. The third step is GARFTase specific (Figure 3) where this enzyme utilizes N10-formyl-
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THF to convert glycinamide ribosyl-5-phosphate (GAR) to formyl-glycinamide ribosyl-5-
phosphate (fGAR). fGAR is converted to amino-imidazolecarboxamide ribosyl-5-phosphate 
(AICAR) in later steps. Then another one-carbon transfer from N10-CHO-THF occurs when amino-
imidazolecarboxamide ribosyl-5-phosphate (AICAR) is converted to formyl-amino-
imidazolecarboxamide ribosyl-5-phosphate (fAICAR) by amino-imidazolecarboxamide ribosyl-
5-phosphate formyl transferase (AICARFTase). Futher conversion of fAICAR yields important 
intermediate inosine-5’-monophosphate (IMP). IMP is significant because it is a precursor of the 
following intermediates: adenosine-5’-triphosphate (ATP) and guanosine-5’-triphosphate (GTP) 
in the ribonucleic acid (RNA) biosynthesis pathway; 2’-deoxyadenosine-5’-triphosphate (dATP) 
and 2’-deoxyguanosine-5’-triphosphate (dGTP) in the DNA biosynthesis pathway.4 
Though folates are instrumental in several biochemical reactions, their physiological 
availability is limited by their chemical nature. Folates cannot be passively diffused across 
biological membrane because they are anionic. Because of that, mammals transport folates across 
membranes with the help of several transporter molecules. These complex transport molecules 
translocate folates as monoglutamates. Inside the cell, the enzyme folylpolyglutamate synthetase 
(FPGS) can metabolize folates to add up to eight molecules of L-glutamic acid residues in the γ-
carboxylic acid portion of each previous glutamate to from folylpoly-γ-glutamate. This process, 
known as polyglutamylation, results in, (i) metabolic trapping of folates inside the cell; (ii) binding 
of folate dependent enzymes and polyglutamylatedTHF at low concentration of the substrate; and 
(iii) greater mitochondrial retention of folates. The polygulamylated folates can be reverted back 
to monoglutamylated form via the action of the enzyme γ-glutamyl hydrolase (GGH) which is 
present in the lysosomes.5 This GGH enzyme, which is less studied than FPGS, has endo- or 
exopeptidase activity depending on the species type. P-glycoprotein (Pgp) and other Multidrug 
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resistance proteins (MRP) have the capability to extrude out monoglutamated folates out of the 
cell via ATP dependent pathways.6 
Figure 3. DNA/RNA via de novo purine bio-synthesis.7-8 
Antifolates are classified into two groups based on the presence or absence of glutamate in 
the side chain. These categories are: classical and non-classical antifolates. Because the transport 
and polyglutamylation depends on presence of terminal glutamate, these two classes of  antifolates 
have different membrane transport and polyglutamylation characteristics.5 The first type, classical 
antifolates, contain a L-glutamic acid at the side chain. Some examples are: methotrexate (MTX), 
aminopterin, pemetrexed (PMX, LY231514, Alimta), raltitrexed (RTX, ZD1694, Tomudex) and 
lometrexol (LMTX) (Figure 4). Due to their structural similarity to folates and folate-metabolites, 
these molecules are transported into the cell via the folate transporters (i.e. RFC, FR and/or PCFT). 
On the other hand, the second type of antifolates lack the terminal L-glutamic acid moiety and thus 
are not transported via regular folate transporters. Instead, they are transported via passive or 
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facilitated diffusion.5-6 Some examples of non-classical antifolates are: pyrimethamine, 
trimethoprim (TMP) and piritrexim (PTX) (Figure 5).  
 
                                    Figure 4. Classical antifolates and their targets.7 
 
 
                                  Figure 5. Non-classical antifolates and their targets.7 
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2. Folate transport 
In mammals there is complete absence of enzymatic mechanism to synthesize folates de 
novo. Also, due to their anionic nature, folates cannot be absorbed by passive diffusion. These 
reasons makes it necessary to have some kind of mechanism that will facilitate active transport of 
folates inside the cell. The mammals indeed have developed molecular mechanisms for folate 
transport and three mechanisms have been discovered. These three mechanisms described in the 
literature are: the reduced folate carrier (RFC), the folate receptors (FRs) and the proton-coupled 
folate transporter (PCFT).9-11 Among these three, reduced folate carrier (RFC) is the dominant 
transporter in normal physiological pH.  Folate receptors (FRs) are also active at physiological pH, 
but their presence is site specific. The two FR types, α and β are proteins attached to cell membrane 
via glycosylphosphatidylinositol (GPI) anchors.12  The third type of folate transporter, the proton-
coupled folate transporter (PCFT), demonstrates pH dependent activation and is optimally 
functional at acidic pH.13-14 
2.1. The Reduced Folate Carrier (RFC) 
Studies have identified RFC to be the major folate transporter in mammals. Since this 
transporter is expressed in almost all major tissues in mammals, it is also the major transporter of 
many antifolate molecules. Chemotherapeutic agents, such as, methotrexate, pemetrexed, and 
raltitrexed are transported by RFC and their therapeutic, as well as, toxic activity is associated with 
the expression of RFC in malignant and normal tissues.15-16 
2.1.1. RFC structure 
Human RFC is a 591 amino acid long protein which is a member of major facilitator 
superfamily (MFS) of transporters. Around 40 years ago, in murine leukemia cells, RFC was first 
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observed and later studies revealed that the rodent RFC is 64-66 percent homologous to the human 
RFC.17 The N- and C-termini of RFC is cytoplasmically oriented and the protein comprises of 12 
transmembrane domains (TMDs). The loop connecting TMD1 and TMD2 contains a N-
glycosylated Asn58.  The large loop between TMD6 and TMD7, which is not conserved among 
species, can be replaced by non-homologous portions from SLC19A3 carrier.18 In hRFC null cells, 
co-expressed TMD1-TMD6 and TMD7-TMD12 domains can restore RFC activity by migrating 
to the plasma membrane.  
2.1.2. RFC distribution 
With its ubiquitous expression and activities at physiological pH, hRFC is the dominant 
folate transport system in human cells. hRFC has been identified in liver and placenta in high level 
and also found in lung, kidney, intestine, bone marrow, intestine, brain and some segments of 
CNS. Other sites where RFC has been detected are: renal tubule epithelium (basolateral 
membrane), colon and small intestine (apical brush border), hepatocyte membrane, cell lining of 
the spinal canal (apical membrane) and choroid plexus (apical membrane). The importance of RFC 
in development has been demonstrated by the finding that targeted homologous recombination to 
inactivate both RFC alleles is embryonic lethal in mice.18 
2.1.3. RFC transport mechanism 
Organic phosphate anions are counter transported against anionic reduced folates by RFC 
but inorganic anions inhibit its activity.18 Thus RFC is an anionic antiporter and its physiological 
substrate, 5-methylTHF, is the major circulating form of folate.18 It has been reported that RFC’s 
affinity for folic acid (Ki ~200 μM) is much lower than its affinity for reduced folates (Ki ~1-5 
μM). The Ki for reduced folate is 50 to 100 times lower than folic acid.  Physiological pH of 7.4 
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provides the optimum microenvironment for RFC and significant decrease in activity is observed 
when the pH goes lower than 7. RFC has to generate substantial electrochemical potential 
difference across the cell membrane to transport folates with two negative charges to overcome 
the challenge of membrane potential.18 RFC transport is neither linked to ATP hydrolysis nor Na+ 
or H+ dependent anion transport. Rather, organic phosphate mediated transmembrane anion 
gradient facilitates its transport activity.19-20 In contrast to their lower concentration in the 
extracellular environment, organic phosphate ions are abundant inside the cell due to their 
formation via ATP-dependent reactions. This gradient of organic phosphates across the cell 
membrane provides the potential for RFC to actively transport folates in an uphill direction.19-20 
2.1.4. RFC in chemotherapy 
For transportation purpose, antifolate agents (e.g. MTX, RTX and PMX) mimicking folates 
are treated by RFC in the same manner. Thus RFC actively transports classical antifolates in the 
same way it actively transports folates.21 To keep an optimum intracellular level of antifolates and 
to trap polyglutamylated folate derivatives inside the cell, sustained transport of these chemical 
agents is critical. Since, plasma concentration of antifolates (e.g. methotrexate, MTX) decrease 
with time, intracellular trapping of mono-glutamate as polyglutamylated antifolates ensures that 
target enzymes, like thymidylate synthase and dihydrofolate reductase, are inhibited. Malignant 
cells developed resistance exploiting this transport requirement and just six years after it provided 
the first metastatic cancer cure, MTX was identified to be resistant in L5178 murine leukemia 
cells. Later studies showed that several other classical antifolates have been rendered ineffective 
due to this transport impairment resistance mechanism developed by cancer cells.22 To circumvent 
this resistance mechanism, drug concentration of antifolates outside the cell could be increased to 
gain some success. Higher concentration of extracellular level of drug forces uptake via alternative 
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mechanisms like passive diffusion, which in-turn results in inhibition of folate metabolizing 
enzymes. The problem with this approach is that increased level of drug will increase intracellular 
concentration both in malignant and non-malignant cell; thus causing toxicity.  
2.2. The folate receptors (FRs) 
Another type of folate transporter protein is the folate receptor which has three subtypes.  
2.2.1. FRs: structure 
The three types of folate receptors are: FRα, FRβ and FRγ and their length varies from 229 
to 236 amino acids. These proteins share 68 to 79 percent amino acid sequence which makes them 
highly homologous. Three FRα and FRβ encoding genes have been identified at chromosome 
11q13.3-q13.5 and an FRγ encoding gene, has been identified at chromosome 11q14.23-24 FRα and 
FRγ contains two and FRβ contains three N-glycosylation sites in their structure. Unlike RFC, 
hFRα and hFRβ are plasma membrane anchored proteins attached through a glycosyl-
phosphatidylinositol (GPI) portion and FRγ is a secreted protein due to the lack of that portion.  
 In 2013 Karsten Melcher and coworkers25 reported the crystal structure of FRα with folic 
acid at 2.8 Å resolution in which they identified that eight disulfide bond stabilizes a globular 
structure of FRα. They also identified a deep open folate-binding pocket formed by amino acids 
which is conserved across receptor subtypes. The inner portion of the binding pocket 
accommodates the pteroate moiety and the glutamate of the folate extrudes as a solvent exposed 
moiety. The solvent exposure enables the glutamate moiety to contain conjugated drugs without 
hampering the receptor binding of folate. Melcher and coworkers25 also described the amino acid 
interaction between the binding pocket and folic acid. The pterin N1 and N2 atoms of folic acid 
form strong hydrogen bonds with the side-chain carboxyl group of Asp81, the N3 and O4 atoms 
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with the Ser174 hydroxyl group, the O4 atom forms two hydrogen bonds with the guanidinium 
groups of Arg103 and Arg106, and the N5-atom forms one hydrogen bond with the His135 side 
chain. The folic acid aminobenzoate is stabilized by hydrophobic interactions with Tyr60, Trp102 
and Trp134, which line the middle of the long ligand binding pocket. Extensive interactions are 
also observed for the glutamate group, which engages six hydrogen bonds, contributed by the side 
chains of Trp102, Lys136 and Trp140, as well as by backbone interactions with His135, Gly137 
and Trp138.25 The antifolates methotrexate and aminopterin (Figure 4) contain an amino group 
instead of the O4 which results in the loss of hydrogen bonds between that atom and Arg103 and 
Arg106 (due to steric clash). This explains why the 4-amino compounds demonstrate low affinity 
for FRα.25 
In 2013, the crystal structure of FRβ was published by Charles E. Dann III and coworkers.3 
The group studied FRβ under neutral and acidic pH conditions and reported six different 
conformations. Their work shows the pH dependence of folate binding via structural 
rearrangement. The transport and non-transport of folate in neutral vs. acidic pH is explained by 
the discovery that the cleft of the receptor goes from open to closed conformation when pH goes 
lower.3 
2.2.2. FRs: distribution 
The apical membrane of polarized epithelial cell lines are the major expression sites for 
FRα. hFRα has been identified in several organs: in the choroid plexus region of the brain and in 
the proximal tubule region of the kidney. The receptor has also been identified in retina, placenta 
and uterus. It is important to note that the expression of FRα in apical surfaces makes the receptor 
inaccessible to systemic circulation and as such to circulating folates. Thus the site specificity of 
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FRα provides a natural protection against the cytotoxicity of FRα-targeted chemotherapeutic 
agents. FRβ expression is also site specific and the receptor has been observed in myelomonocytic 
hematopoietic cells, thymus, placenta and spleen. The expression in hematopoietic cells is not 
ubiquitous: monocytes contain FRβ (CD co-expressed) but CD34+ normal hematopoietic 
progenitors do not.26 Low level secretion of hFRγ has been observed in lymphoid cells at several 
sites: spleen, thymus, and bone marrow. Site specificity of FRα and FRβ, low expression of FRβ 
and transcytosis absorption mechanism utilized by FRα gives these receptors unique advantage 
compared to RFC as drug targets. These characteristics reduce the dose limiting toxicity of FR 
targeted antifolates that have relatively low or no transport via RFC that is otherwise observed in 
currently marketed non-specific antifolate drugs.  
Along with its site specific expression under normal physiological condition, FRα has also 
been observed in several malignant tissues: non-mucinous adenocarcinomas of ovary, uterus and 
cervix, and ependymal brain tumors. Positive correlation between FRα level and malignancy stage 
and grades has been identified.31 FRβ has also been found in several malignant tissues:  chronic 
myelogenous leukemia (CML) and acute myelogenous leukemia (AML) [but not Acute 
Lymphoblastic Leukemia (ALL)]. The identification that the FRα and FRβ expressed in the 
malignant tissues are functional makes them a suitable target for cancer imaging and 
chemotherapeutic antifolates.26  
2.2.3. FRs: transport 
FRs internalizes folates via endocytosis process. Binding of a folate molecule on the cell 
surface folate receptor triggers conformational change in the receptor that initiates invagination in 
the plasma membrane. At the site of folate binding, the invagination produces a vesicle (endosome) 
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and then the vesicle internalizes to start its migration into the cytoplasm.12, 27-29 The pH inside the 
endosome reaches 6.0 to 6.5 when it is in the cytoplasm and the acidification causes 
conformational change in the FR-substrate complex. This conformational change stimulates the 
dissociation of the folate form the receptor and the ligand then follows a trans-endosomal pH 
gradient to release into the cytoplasm. The folate releasing endosome returns to the plasma 
membrane to get fused with it and thus FR gets back to the initial apo-state. This recycling of the 
FR enables the receptor to repeat its transporting activity.12, 27-29 
2.2.4. FRs in chemotherapy 
Due to their selective expression and high affinity toward reduced folates, FRs are 
attractive target for selective anticancer drugs. As mentioned earlier, FRα is overexpressed in 
different malignant tissue and in almost all ovarian cancer tissue (90%). In ovarian cancer, 
association has been identified between status and grade of the malignancy and FRα expression 
level.30 FRβ expressed in myeloid leukemia cells, are capable of transporting folates unlike the 
FRβ expressed in normal hematopoetic tissue.31 FRs have been targeted via several cytotoxic 
agents: antifolates, folate-conjugates, radionuclides etc.; however, most of these have 
demonstrated to be non-selective methods.31 The currently used folate targeted agents (e.g. MTX, 
RTX and PMX) are also transported by RFC, which makes them cytotoxic to normal cells. Folate 
and pteroate conjugated prodrugs (e.g. mitomycin C conjugate), which are unlikely to bind with 
RFC, have been designed to circumvent the selectivity problem, but these drugs have not proven 
to be much successful due to their premature cleavage. The early release of cytotoxic moiety before 
internalization results in reduced therapeutic effect towards malignant cells and increased toxicity 
towards normal proliferating cells.  Even if these molecules are internalized, their intracellular 
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cleavage generates free folates that feeds the tumor cells as a nutrient.  Folate analogs which target 
FRs and are themselves cytotoxic will be able to circumvent the two challenges stated here.  
2.3. The proton-coupled folate transporter (PCFT) 
The PCFT encoding gene was identified on chromosome 17q11.2 and the protein was 
discovered in 2006. A member of the solute transfer superfamily of proteins, PCFT absorbs folates 
in the upper intestine. The optimum pH for PCFT activity is acidic (pH 5.5) and as such it can 
transport folates into non-intestinal tissue when the microenvironment is acidic. PCFT acts as a 
proton symporter, transporting folates down an electrochemical concentration gradient along with 
protons. Along with its acidic activation pH, substrate specificity of PCFT differentiates it from 
the ubiquitous folate transporter RFC. It has been reported that PCFT shows high affinity for folic 
acid and low affinity for PT523 (a non-polyglutamable aminopterin analog), contrasting the 
opposite affinity pattern demonstrated by RFC.13, 32-33 
2.3.1. PCFT: structure 
Via immunofluorescence analysis of hemagglutin (HA)-tagged hPCFT molecules it has 
been identified that the hPCFT is a 459 amino acid long protein which composes of 12 
transmembrane domains.34-36 PCFT does not require to be N-glycosylated to function as a 
transporter.31 
2.3.2. PCFT: expression 
Although PCFT has been identified in several organs: placenta, kidney, liver, retina and 
brain, the major expression site is the intestine (specially the duodenum and upper jejunum 
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portion). In the acidic microenvironment of its upper intestinal expression sites, PCFT constitutes 
the major dietary folate absorbing mechanism.13 
2.3.3. PCFT: transport 
PCFT medicated folate transport is an electrogenic process, meaning a net translocation of 
positive charge takes place. PCFT is a symporter protein that couples uphill flow of folates with 
the downhill flow of protons. In accordance with a proton-coupled process, greater unidirectional 
folate transport and significant transmembrane folate concentration gradient is resulted by 
transvesicular pH gradient. A striking feature of PCFT is its optimal activation at an acidic pH, 
while almost total inactivation occurs at physiological pH. Maximum transportation of folates by 
PCFT occurs at pH 5 to 5.5 and the activity gradually decreases with increased pH; almost no 
activity is detected above pH 7.33-35 
2.3.4. PCFT in chemotherapy 
The microenvironment of human solid tumor tissue is mostly acidic.36-37 Since hPCFT is 
expressed in a broad range of solid tumors, this acidic microenvironment facilitates folate transport 
via PCFT.36-38 Although complete understanding of PCFT transport is still in an ongoing stage, 
classical antifolate transport by this receptor has been reported in the literature.34 Among classical 
antifolates, MTX, RTX, PMX show cytotoxic activity at physiological pH but MTX and RTX 
loses the activity at lower pH. PMX still shows cytotoxic activity at lower pH because unlike MTX 
and RTX, this molecule is transported by both RFC and PCFT.14, 39 The dose limiting toxicity of 
PMX is generated from its dual transport by RFC and PCFT at regular physiological pH. As such, 
antifolate designed to be transported by only PCFT and not by RFC will be able to circumvent 
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toxicity to normal tissue. It is important to note that most solid tumors have an acidic 
microenvironment (pH 6.0 – 6.8) where only PCFT transports folates and antifolates efficiently.   
3. Glycinamide-ribonucleotide formyltransferase (GARFTase) 
 The de novo synthesis and salvage pathways are two synergistic purine synthesis processes 
that generate nucleotides necessary for nucleic acid synthesis and metabolism. Targeting enzymes 
involved in these pathways may be a route to gain anti-proliferative effects. There are six 
multifunctional enzymes that take part in the 10 step purine de novo biosynthesis. Three of these 
six enzymes are mono functional, two are bifunctional and one is trifunctional. Conversion of 
phosphoribosyl pyrophosphate to inosine monophosphate occurs in this biosynthesis process.  
 The trifunctional peptide glycinamide ribonucleotide formyltransferase (GARFTase), 
which modulates purine biosynthesis, was first reported by Warren and Buchanan.40 The three 
functional parts of this peptide are: glycinamide ribonucleotide synthetase (GARSase), GARFTase 
and aminoimidazole ribonucleotide synthetase (AIRSase) and they catalyze the second, third and 
fifth steps of the biosynthesis process respectively. The C-8 of inosinic acid (IMP) is incorporated 
by GARFTase. In the catalytic process, GARFTase removes a formyl group from N10-formyl-THF 
to produce tetrahydrofolate and transfers the formyl to glycinamide ribonucleotide (GAR) to 
produce formylglycinamide ribonucleotide (fGAR). Because of its mechanistic role in formyl 
transfer,41-42 and biological role in nucleic acid precursors synthesis,43  GARFTase is of 
considerable interest as a cytotoxic target. 
 In RNA and DNA biosynthesis, purine nucleotides act as building blocks. This makes the 
de novo purine biosynthetic pathway enzymes viable targets for chemotherapeutic agents. This 
potential was demonstrated by the mechanism of action of the cytotoxic agent 5,10-
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dideazatetrahydrofolate, which inhibits de novo purine biosynthesis via the inhibition of 
GARFTase.44  
3.1. GARFTase: structure 
hGARFTase is part of a 110 kDa trifunctional peptide that also catalyzes two other steps 
in the purine biosynthesis pathway.45 With its natural substrate β-GAR (2.2 Å), hGARFTase has 
been studied at pH 4.2 (1.7 Å), pH 8.5 (2 Å) and pH 8.5.46 At near physiological pH, hGARFTase 
has been studied with different inhibitors in the bound state. These inhibitors include 10-
trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-CF3CO-DDACTHF) (2 Å)
47 
and several other antifolates.48 The X-ray crystal structures of hGARFTase bound with PMX and 
similar 6-substituted pyrrolo[2,3-d]pyrimidines has also been reported.49   
3.2. GARFTase: catalysis 
The catalytic mechanism of GARFTase has been elucidated via a series of kinetic studies 
performed on E. coli, human and murine sources. These studies show the formation of a tetrahedral 
structure through the nucleophilic attack of the GAR amino group on the formyl carbon of the co-
substrate in the catalytic pocket. It has been proposed that, the proton transfer required for the 
formation and collapse of this tetrahedral intermediate is medicated by a water molecule.50 
During cofactor binding, the Asp144 of hGARFTase forms a salt bridge with the 
imadozolium of His108 and the substrate formyl group is hydrogen bonded with the protonated 
imadozolium of His108 and Asn106. The GAR attacks the activated formyl group with its free 
base amino group and forms the tetrahedral intermediate. A catalytic water molecule, hydrogen 
bonded to the carboxylate of Asp144, mediates proton transfer from GAR to the N10 of folate 
which leads to the collapse of the tetrahedral intermediate. The scheme is shown in figure 6.42 
 18 
 
 
                            Figure 6. Catalytic mechanism of GARFTase.42 
3.3. GARFTase: inhibitor binding 
 The crystal structure of hGARFTase at pH 7 was resolved by Zhang et al.47  at 1.98 Å as a 
binary complex with the inhibitor molecule 10-CF3CO-DDACTHF (PDB entry 1NJS). The crystal 
structure showed that the substrate binding pocket of hGARFTase is composed of three domains: 
the pteridine binding cleft, the benzoylglutamate binding region, and the formyl transfer region. 
Pteridine Binding Cleft. Similar to the N10-formyl-5,8,10-trideazafolic acid (N10-formyl-
TDAF) binding in the E. coli GARFTase complex (PDB entry 1C2T), the diaminopyrimidinone 
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portion of 10-CF3CO-DDACTHF is deeply buried in the active site cleft of hGARFTase. 
Compared to N10-formyl-5,8,10-trideazafolic acid, 10-CF3CO-DDACTHF shows more flexibility 
during binding due to the absence of a fused benzene ring. Thus this monocyclic analog can adapt 
relatively easily at the binding site to facilitate gem-diol interaction with the protein. The N2 of 10-
CF3CO-DDACTHF is within hydrogen bonding range (3.1 Å) of the backbone carbonyl oxygen 
of Glu141, because of its relatively higher tilt (15°) compared to the quinazoline ring of N10-formyl- 
trideazafolic acid. The quinazoline ring of N10-formyl-trideazafolic acid, mimics the 
diaminopyrimidinone ring of 10-CF3CO-DDACTHF, conserves all the key interactions and 
engages in additional hydrogen bonding in the binding site. Several hydrophobic amino acids in 
the binding site (Leu85, Ile91, Leu92, Phe96, and Val97) forms a deep pocket to hold the 
diaminopyrimidinone. Six hydrogen bonds are formed between the diaminopyrimidinone ring and 
the amides and carbonyl residues of several binding pocket amino acids (Arg90, Leu92, Ala140, 
Glu141, and Asp144). Two additional hydrogen bonds are formed between the 
diaminopyrimidinone and two ordered water molecules (W18 and W70). The N8 nitrogen of 10-
CF3CO-DDACTHF forms hydrogen bonds with the carbonyl oxygen of Arg90 and an ordered 
water molecule (W70).  
Glutamic Acid Tail. In the GARFTase bound 10-CF3CO-DDACTHF complex, two amino 
acids, Ile91 and Ser118, forms a hydrophobic pocket to accommodate the p-aminobenzoate portion 
of the inhibitor. The carbonyl group and the phenyl ring remain in the same plane. The p-
aminobenzoate is on a perpendicular plane whereas, the aliphatic linker is on a parallel plane 
relative to the aliphatic stem of the diaminopyrimidinone ring. Although the glutamate moiety is 
solvent exposed, its structure is relatively well-ordered in the enzyme bound state. The Arg64 
moiety of the enzyme forms a salt bridge (2.7 Å) with the α-carboxylate of the glutamate, thus 
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forcing the γ-carboxylate to orient toward the solvent. The  α-glutamate carboxylate forms a 
hydrogen bond with the Ile91 moiety as well (2.8 Å). 
Formyl Transfer Region and the Gem-Diol Structure. Similar to the transformation of N10-
formyl-trideazafolic acid in the E. coli GARFTase (PDB 1C2T) bound state,   the trifluoromethyl 
ketone  of hGARFTase bound 10-CF3CO-DDACTHF has been identified to be converted into a 
gem-diol. The formyl transfer region of the enzyme shows extensive interaction with the gem-diol 
of the inhibitor. The Asp144 of the formyl transfer region forms hydrogen bonds (2.5 and 2.7 Å) 
with both the hydroxyls of the gem-diol via its carboxylate group. Another amino acid moiety, 
His108, forms hydrogen bonds in a similar fashion with both the hydroxyl groups (2.7 Å and 3.1 
Å) using the N3 of its imidazole ring. The backbone carbonyl oxygen of Gly117 forms an 
additional hydrogen bond with one of the diol-hydroxyl group.  
3.4. GARFTase: inhibitors 
Some representative GARFTase inhibitors with bicyclic scaffold are reviewed and listed 
in Table 1. 
3.4.1. GARFTase inhibitors: 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydro-
pyrimido[5,4-b][1,4]thiazines 
Lometrexol. Synthesized by Taylor and coworkers51 in 1985, lometrexol (LMTX, Table 1) 
was the first GARFTase inhibitor to reach the clinical trial stage. LMTX is the 6-(R)-isomer of the 
compound 5,10-dideazatetrahydrofolic acid (DDATHF). The discovery of lometrexol was the first 
step in establishing GARFTase and the de novo purine biosynthesis as a potential target for 
anticancer chemotherapy. Although lometrexol showed poor effect on DHFR and TS, it was a 
substrate for PFGS and a potent inhibitor of GARFTase (Ki = 6 nM).
52 Among the equipotent 
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diastereomers of 5,10-dideazatetrahydrofolic acid, the one mimicking the tetrahydrofolates, the 
(6R)-diastereomer, was taken further in the development process. Despite its demonstrated potency 
LMTX showed severe toxicities (myelosuppression and mucositis) in phase I trials. The non-
selective transport of LMTX by both RFC and FRs have been identified as the cause of its 
GARFTase inhibitors: 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-
dihydro-pyrimido[5,4-b][1,4]thiazines (Table 1) 
Structure Compound Biological 
Activity 
Ref. 
 
 
 
LMTX 
(6-(R)-
DDATHF) 
 
hGARFTase (Ki) 
6 nM 
 
52 
 
 
LY-222306 
(6-R,S) 
 
hGARFTase (Ki) 
0.77 nM 
 
CCRF-CEM 
(IC50) 
27 nM 
 
53 
 
 
LY-254155 
(6-R,S) 
LY-309887 
(6-R) 
 
hGARFTase (Ki) 
2.1 nM 
 
CCRF-CEM 
(IC50) 
27 nM 
 
54 
 
 
AG-2034 
 
hGARFTase (Ki) 
28 nM 
 
CCRF-CEM 
(IC50) 
2.9 nM 
 
55 
 
 
AG-2037 
(pelitrexol) 
 
hGARFTase (Ki) 
0.5 nM 
 
 
 
56 
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cumulative toxicity. Indiscriminate absorption and accumulation results in the increased cellular 
concentration of the drug in both normal and malignant cells that causes cytotoxicity.57 
 LY-309887. A novel class of classical antifolates were synthesized by Habeck et 
al.53 in which the 1’,4’-phenyl group of LMTX was replaced with a 2’,5’-furan (LY-222306) and 
a 2’,5’-thiophene (LY-254155) (Table 1). Both compounds, LY-222306 and LY-254155, as 
mixtures of diastereomers were found to inhibit the growth of CCRF-CEM cell line (IC50 = 27 nM 
and 2.3 nM, respectively) and were inhibitors for hGARFTase (Ki = 0.77 nM and 2.1 nM, 
respectively). Resolution and testing of diastereomers revealed the compound 6R-2’,5’-thienyl-
5,10-dideazatetrahydrofolic acid (LY-309887, Table 1) to be more potent than LMTX in murine 
C6H mammary tumor model and in several  xenografts. LY-309887 was 9-times more potent than 
LMTX against GARFTase and was more active against two pancreatic xenografts and in the 
human LX-1 lung carcinoma model. However, similar to LMTX, LY-309887 showed cumulative 
toxicity in phase I clinical trials attributable to nonselective transport via RFC into normal cells. 
 AG-2034 and AG-2037. AG-2034 (Table 1) is a compound structurally similar to LY-
309887 (Table 1), which was designed using the x-ray crystal structure of GARFTase.55 AG-2034 
is a potent inhibitor of hGARFTase with Ki = 28 nM and the molecule is transported by FRs more 
effectively than LMTX. AG-2034 inhibited L1210 and CCRF-CEM cell lines (IC50 = 4.0 nM and 
2.9 nM, respectively) and showed in vivo antitumor activity in lung carcinomas, lymphosarcomas, 
mammary and colon adenocarcinomas and melanoma. AG-2034 did not show the cumulative 
myelosupressive effect of LMTX, but did show mucositis and diarrhea in phase I clinical trial.58 
Another LMTX analog AG-2037 (pelitrexol, Table 1), has the configuration reversed at C-6 
compared to LMTX. Unlike AG-2034, it contains a pyrido[2,3-d]pyrimidine scaffold (same as 
LMTX) and methylated thiophene in the sidechain. AG-2037 demonstrated potent antitumor 
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activity in several in vitro and in vivo studies and proved to be a potent GARFTase inhibitor (Ki = 
0.5 nM). AG-2037 was determined to be well tolerated in several phase I trials and phase II trial 
on advanced metastatic colorectal cancer patients was conducted.59-60 However, development of 
the molecule was discontinued due to a lack of single agent efficacy.60 
3.4.2 GARFTase inhibitors: FRα- and PCFT-substrates49, 61-64 (Table 2) 
Cmpd. Structure RFC 
IC50 in 
nM 
FRα 
IC50 in 
nM 
PCFT 
IC50 in nM 
KB 
IC50 in nM 
KB 
  PC43-10 RT16 R2/hPCFT4 KB(RFC/FRα/PCFT) (+Thd/Ade/ 
AICA) 
11 6-pyrrole/3C/phenyl 648.6 
(38.1) 
4.1 (1.6) 23.0 (3.3) 1.7 (0.4) Ade/AICA 
12 6-pyrrole/4C/phenyl >1000 6.3 (1.6) 213 (28) 1.9 (0.7) Ade/AICA 
13 
(PMX) 
5-pyrrole/2C/phenyl 30.6 (6.2) 18.2 
(3.8) 
22.3 (8.6) 9.94 (3.11) Thd/Ade 
14 5-pyrrole/3C/phenyl 68.8 
(21.2) 
72.0 
(27.1) 
329 (61) 49.5 (13.2) Ade 
4 5-pyrrole/4C/phenyl 56.6 (5.8) 8.6 (2.1) 840 (90) 12.7 (5.4) Ade 
16 6- pyrrole /3C/thieno 101.0 
(16.6) 
0.31 
(0.14) 
3.34 (0.26) 0.26 (0.03) Ade/AICA 
19 6- pyrrole /4C/thieno >1000 1.82 
(0.28) 
43.4 (4.1) 0.55 (0.10) Ade/AICA 
18 5- pyrrole /3C/thieno 116.0 
(22.5) 
109 (44) 312 (90) 211 (58) Ade 
5 5- pyrrole /4C/thieno 38.3 (6.6) 49.3 
(11.5) 
141 (40) 66.0 (14.4) Ade 
 
Novel 5-substituted and 6-substituted classical pyrrolo[2,3-d]pyrimidine antifolates with 
anti-tumor activity have been reported by Gangjee and coworkers49, 61-64 (Table 2). These 
 24 
 
molecules comprise of a varying array of aliphatic and/or aromatic groups in the side chain linker. 
Among the 6-substituted compounds, the 3- and 4- carbon chain analogs showed the most potent 
inhibition against KB and IGROV1 tumor cell lines.49, 61-62 
 
 Figure 7. Representative 5-substituted and 6-substituted pyrrolo[2,3-d]pyrimidines 
with only GARFTase inhibition or GARFTase/AICARFTase dual inhibition.49, 63-64 
In vitro studies on FR expressing CHO cells revealed that most of the 6-substituted 
compounds with a phenyl or a thiophene group on the side chain are FR selective over RFC, while 
the corresponding 5-substituted compounds are not selective.  The shorter linker length (2C to 4C 
for phenyl and 2C to 5C for thiophene) in the 5-substituted compounds are usually associated with 
PCFT activity.49, 63-64 The protection studies indicated that 6-substituted sidechain phenyl and 
thieno compounds are mainly GARFTase inhibitors, whereas 5-substituted 3C/4C sidechain 
phenyl and thieno compounds are mainly GARFTase/AICARFTase dual inhibitors. 
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II. CHEMICAL REVIEW 
Several five and six membered heterocycles have been identified to have biological activity 
and among them pyrrolo[2,3-d]pyrimidines are a notable group. Due to their structural similarity 
with purines and folate metabolites, different pyrrolo[2,3-d]pyrimidine compounds have been 
synthesized and biologically evaluated. In this section, procedures to synthesize pyrrolo[2,3-
d]pyrimidine reported in the existing literature has been discussed in detail. The three major 
approaches to synthesize 5-substituted, 6-substituted and 5,6-disubstituted pyrrolo[2,3-
d]pyrimidines are: 1) from pyrimidine precursors, 2) from pyrrole precursors and 3) from furan 
precursors, which are discussed. 
1. Pyrrolo[2,3-d]pyrimidine from pyrimidine  
 In the literature pyrimidine has been described as the main precursor of  pyrrolo[2,3-
d]pyrimidines.  
 
Scheme 1. Synthesis of pyrrolo[2,3-d]pyrimidines 28. 
The synthesis of 6-substituted 2-amino-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one 28 
(Scheme 1) from 1,3-dioxolane-2-propanoic acid, α-cyano-2-methyl-ethyl ester 25 and guanidine 
26  was first reported by Seela and Luekpke. 65 
The synthesis of unsubstituted pyrrolo[2,3-d]pyrimidines 31 (Scheme 2) and 34 by the 
reaction of chloroacetaldehyde 30 with 2-amino-6-alkylamino-4-hydroxypyrimidines 29 and 6-
amino-1,3-dimethyluracil, 32 respectively was first reported by Noell and Robins.66 
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Scheme 2. Synthesis of pyrrolo[2,3-d]pyrimidines 31 and 34 
The synthesis of pyrrolo[2,3-d]pyrimidine with trifluoromethyl substitution (Scheme 3) 
was reported by Gibson et al.67 They reported the reaction of the oxime of bromotrifluoroacetone 
36 with 35 (excess) in DMF to afford the C-5 alkylated pyrimidinone 38 in 80% yield.  
 
Scheme 3. Synthesis of 8-trifluoromethyldeazaguanine 38. 
Scheme 4. 5-Substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidine 41, 42 and 43. 
5,6-Disubstituted-pyrrolo[2,3-d]pyrimidine was also synthesized by Gibson et al.67 2-
Chloro-2-cyanoethanal 40 was reacted with 39 (Scheme 4) to afford exclusively the 7-yano-7-
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deazaguanine 41. Substituents at C-5 and C-6 were obtained by brominating the primary 
deazaguanine 41 with N-bromosuccinimide in DMF to afford the 7-cyano-8-bromo derivative 42. 
These transformations established methods for the synthesis of a wide range of 5-substituted, 6-
substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidines. 
 
 
Scheme 5. Synthesis of pyrrolo[2,3-d]pyrimidines 48 and 50 and furo[2,3-d]pyrimidines 47. 
 A detailed study of the reaction of 2,6-diamino-4-hydroxypyrimidine 44 (Scheme 
5) with various -halo aldehydes and ketones was reported by Secrist and Liu.68 They reported 
that the cyclization occurred via one of two modes to produce either the pyrrolo[2,3-d]pyrimidine 
and/or the furo[2,3-d]pyrimidine. Thus -halo ketones, chloroacetone 45 and 3-bromo-2-butanone 
46, afforded both the furo[2,3-d]pyrimidine 4 and the pyrrolo[2,3-d]pyrimidine 47, whereas 49 
produced only the pyrrolo[2,3-d]pyrimidine 50 on reaction with 44. They suggested that to 
exclusively afford pyrrolo[2,3-d]pyrimidines, a critical electron density is necessary for the C5 of 
the pyrimidine nucleus to react with the -carbon atom of the -halo aldehydes or ketones. 
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Scheme 6. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 57. 
Taylor et al.69 reported a synthetic scheme for 6-substituted pyrrolo[2,3-d]pyrimidines. 
Chloromercuration of 2-pivaloylamino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidine yielded a 10:l 
mixture of the 6-chloromercuri derivative 52 and the 5-chloromercuri derivative 53 in 74% overall 
yield (Scheme 6). Without separation, this mixture of chloromercuri derivatives were treated with 
iodine in dichloromethane to give the corresponding iodo derivatives (54 and 55) from which the 
desired 6-iodo compound 54 was readily separated in 64% yield by column chromatography. A 
palladium- catalyzed carbon-carbon coupling reaction of this 6-iodopyrrolopyrimidine derivative 
54 with dimethyl 4-ethynylbenzoyl-L-glutamate 56 led to the C-6 coupled derivative 57 in 78% 
yield. 
 29 
 
Scheme 7. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 57 and 60. 
Another scheme for functionalizing the 6-position of pyrrolo[2,3-d]pyrimidine was 
reported by Taylor et al.70 A more efficient synthesis of 57 resulted from the use of an 
ethoxycarbonyl N-7 protecting group rather than an N-Ts group (Scheme 7). 
 
Scheme 8. Synthesis of pyrrolo[2,3-d]pyrimidine 62 from 6-amino-5-pyrimidylacetaldehydes 61. 
A novel synthetic approach for PMX (Scheme 8) was described by Taylor et al.70 in which 
spontaneous cyclization of sodium 4-[3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-4-
nitrobutyl]benzoate 61 occurred. Conversion of acid 62 to PMX involved standard peptide 
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coupling with diethyl L-glutamate using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the coupling 
agent in presence of N-methylmorpholine and final saponification.  
Scheme 9. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization. 
Fisher indole cyclization of 6-(phenylhydrazino)uracil 63 to 9H-pyrimido[4,5-b]indole-
2,4-dione 64 (Scheme 9) was reported by Wright et al.71 Several authors have employed the Fischer 
indole cyclization of 4-pyrimidinylhydrazones 65 (Scheme 9) to afford the pyrrolo[2,3-
d]pyrimidine ring system 66. The applicability of the Fischer-indole cyclization to the synthesis of 
pyrrolo[2,3-d]pyrimidines, however is limited by the high reaction temperatures and the steric 
constraints for the [3,3] sigmatropic rearrangement involved in the mechanism. 
Scheme 10. Synthesis of pyrrolo[2,3-d]pyrimidine 78. 
A synthetic scheme for the synthesis of 2-amino-4-methylpyrrolo[2,3-d]pyrimidine 
(Scheme 10) had been reported by Gangjee and coworkers.72 Compound 73 and guanidine 
carbonate at reflux in absolute ethanol in the presence of triethylamine or sodium methoxide  
afforded 74. Compound 74 was converted to 75 with phosphorus oxychloride at reflux in 68% 
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yield. Condensation of benzylamine with 75 in the presence of triethylamine under reflux in n-
BuOH afforded the bicyclic compound 76 in 50% yield. Compound 76 was oxidized to aromatic 
compound 77 using MnO2. Sodium in liquid ammonium at -78 °C afforded the debenzylation of 
77 to 78. 
 
Scheme 11. Synthesis of pyrrolo[2,3-d]pyrimidines 82. 
Protected 5-acetaldehyde pyrimidine 81 was subjected to intramolecular cyclization to synthesize 
pyrrolo[2,3-d]pyrimidine 82 (Scheme 11) by Sakamoto and coworkers.73 Compound 81 were 
synthesized by palladium(0) catalyzed coupling of the appropriate 2,4-disubstituted-5-bromo-6-
acetamido pyrimidine 79 with (Z)-1-ethoxy-2-(tributylstannyl)ethane 80. The same methodology 
was used for the synthesis of pyrrolo[3,2-d]pyrimidines. 
2. Pyrrolo[2,3-d]pyrimidine from pyrrole 
 
Scheme 12. Synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 87. 
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4-Amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 87 (Scheme 12) was synthesized by 
Taylor et al.74 Tetracyanoethylene 83 was converted by the action of hydrogen sulfide to 2,5-
diamino-3,4-dicyanothiophene 84, which was rearranged with alkali to 5-amino-3,4-dicyano-2-
mercaptopyrrole 85 as described by Middleton et al.75  Treatment of 85 with methyl orthoformate 
followed by alcoholic ammonia gave 4-amino-5-cyano-6-methylmercaptopyrrolo[2,3-
d]pyrimidines 86. Raney nickel desulfurization of 86 then gave 87.  
Scheme 13. Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 92. 
Taylor et al.76 also reported the synthesis of 4-amino-5-methyl-pyrrolo[2,3-d]pyrimidine 92 (R = 
CH3) (Scheme 13) from 2-amino-3-cyano-4-substituted pyrroles 92 which in turn were obtained 
from malonodinitrile and the appropriate -aminoketones 88. Treatment of pyrrole 90 with 
triethylorthoformate followed by ammonia resulted in the imidine intermediates 91 which 
underwent cyclization with sodium methoxide in pyridine to afford the pyrrolo[2,3-d]pyrimidine 
92.  
A 5,6-dihydro-pyrrolo[2,3-d]pyrimidine analog of PMX was synthesized by Taylor and 
coworkers77 (Scheme 14). A manganic triacetate dihydrate mediated radical cyclization of racemic 
methyl N-crotyl-N-[1-(3,4-phenyl)-eth-1-yl)malonamide 97, afforded a diastereomeric mixture of 
the 3-carbomethoxy-2-pyrrolidinone 98. Compound 97 was in turn obtained by alkylation of 
racemic 1-(3,4-dimethoxy-phenyl)-ethylamine 93 with crotyl bromide 94 followed by a DMAP 
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catalyzed acylation with methyl malonyl chloride 96. The pyrrolidinone 98 was converted to the 
thiolactam 99 with P2S5 followed by cyclocondensation with guanidine to afford the N7-protected 
5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine 100. Palladium catalyzed cross-coupling with 
diethyl-4-iodobenzoyl-L-glutamate fortuitously afforded the ethano-bridged derivatives, and not 
the expected vinyl-bridged derivatives, by double bond migration. This compound was then 
elaborated to analogs of PMX. 
 
Scheme 14. Synthesis of N7-substituted analogs of PMX.  
Utilizing a guanidine cyclization of a preformed 3-carbethoxy-2-thiopyrrolidine 
intermediate 105 (Scheme 15) as the key step, Barnett et al.78 reported the synthesis of a 2-amino-
4-oxo-5,6-dihydropyrrolo[2,3-d]pyrimidine 106. This intermediate was in turn prepared over 
several steps from 4-propionaldehyde benzoic acid tert-butyl ester 101. Compound 106 was 
reduced to the pyrrolo[2,3-d]pyrimidine intermediate, 107 which was then elaborated to PMX in 
several steps. 
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Scheme 15. Synthesis of pyrrolo[2,3-d]pyrimidine 107 and PMX. 
 3. pyrrolo[2,3-d]pyrimidines from furans 
 
Scheme 16. Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 110. 
Taylor and coworkers79 reported an unexpected ring transformation/ring annulation 
sequence in which 2-amino-3-cyanofurans 108   (Scheme 16) on cyclization with amidines 109 
afforded the corresponding pyrrolo[2,3-d]pyrimidines 110. 
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III. STATEMENT OF THE PROBLEM 
 The idea of selective tumor targeting using FRs has been discussed in the literature. 
However, the concurrent transport of antifolate ligands by RFC, foils the practical application of 
this approach.  For that reason, avoiding the RFC transport of the ligands and targeting FR is a 
prime objective to attain selectivity in antifolate therapy. PCFT specific ligand development is 
another approach that has potential for selectivity. Combining these two concepts, an antifolate 
which is transported by FRs and/or PCFT over RFC and targets intracellular enzymes (e.g. 
GARFTase, AICARFTase) is the desired molecule to be designed as a potential selective 
anticancer agent.  
(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoyl)-L-
glutamic acid and its analogs with variation in the chain length and/or side chain aromatic 
group as GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC: 
     
                            Figure 8. The structures of classical 2-amino-4-oxo-5-substituted pyrrolo[2,3-
d]- pyrimidine antifolates 4 and 5 (Table 2).  
At physiological pH, RFC dominantly transports the anionic folate analogs into the cell.  
Tissue specific FRs (FRα and FRβ) performs endocytosis to transport folates into the cell in the 
tissues where they are expressed (e.g. FRα in kidney, choroid-plexus and several malignancies 
including 90% of ovarian cancer; FRβ in placenta, spleen, and thymus) and functions at 
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physiological pH.26, 29, 80 The site restrictive expression of FRs make them potential mechanisms 
for tissue selective drug transport. In contrast to these two types of folate transporters, PCFT 
transports folates predominantly at acidic pH, which usually is the microenvironment in and 
around solid tumors.29, 81 Due to its expression being restricted in the apical brush border of the 
proximal tubule of the kidney, FRα does not cause renal toxicity that might otherwise have resulted 
by classical antifolates. Although FRβ expression occurs both in normal hematopoietic cells and 
myeloid leukemia cells, only those proteins expressed in malignant cells can bind folate analogs.31, 
82 PCFT only transports folates in the acidic environment of the small intestinal expression site; 
but does not transport in the kidney or liver due to the lack of an acidic environmnet.11 In study of 
solid tumor cell lines, 29 out of 32 cell lines demonstrated transport at acidic pH, which is 
conducive to PCFT transport.1 
Different approaches to utilize FR transport of folates has been studied as targeted 
anticancer therapy which includes: folate-conjugates, radionuclides, antifolate cytotoxins etc.4, 83-
85 One technique to take advantage of the high affinity of FRs for folic acid was to attach an active 
compound with folic acid, thus using the folic acid as the targeting component.86-87  Delivery of 
antisense oligonucleotides and radioactive compounds used for therapy and imaging has also been 
performed using this method.88  However in most of the cases tumor selectivity was not attained.  
The clinically available classical antifolate PMX inhibits KB cell line (IC50 9.94 nM), as 
well as FRα (IC50 18.2 nM) and PCFT (IC50 18.2 nM) expressing CHO cell lines. However, PMX 
is also transported by RFC (IC50 30.6 nM) and thus lacks FRα and/or PCFT selectivity over RFC. 
Research has revealed that TS is the primary target of PMX, not GRAFTase.85 Novel classical 
antifolates 4 and 5 (Figure 8), with a pyrrolo[2,3-d]pyrimidine scaffold and 5-substitution, has 
been reported by Gangjee and coworkers63-64 which are GRAFTase inhibitors.  These compounds 
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with varying lengths of carbon linker side-chains have been shown to possess potent KB cell 
inhibitory activity, which has been ascribed to their ability to be transported via FRs (FRα and 
FRβ) and RFC. Among the 5-substituted compounds, those with 4-carbon linker chains and a 
phenyl (4) or thiophene (5) ring (Figure 8) in the side chain showed significant inhibitory activity 
against CHO cell lines expressing FRα. Compound 4 showed FRα selectivity over RFC, but  5 did 
not show such selectivity. Protection studies revealed that both 4 and 5 had potent inhibitory effect 
on GARFTase. This activity was responsible for disrupting the de novo purine biosynthetic 
pathway inside the cell and that was the major mechanism of cytotoxicity. Studies also revealed 
that 4 (containing a phenyl in the side chain) possesses some PCFT activity, and the activity 
improves significantly for 5 (containing a thiophene in the side chain). Despite the molecules being 
potent KB cell inhibitors and FRα substrates, they showed some limitations. Compound 4 showed 
limited PCFT activity and 5 did not have selectivity for FRα over RFC.63-64 Thus additional SAR 
investigations were warranted to optimize the transport selectivity and retain the anticancer activity 
of 5-substituted pyrrolo[2,3-d]pyrimidine compounds.    
 
Figure 9. The structures of proposed classical 2-amino-4-oxo-5-substituted pyrrolo[2,3-
d]- pyrimidine antifolates 6-10. 
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With 4 and 5 as the lead, important SAR variations in the side-chain aromatic group were 
proposed. This included substituting the thiophene with a furan, or a substituted phenyl, or a 
regioisomer of the 1,4-phenyl; with varying  lengths of the aliphatic side-chain as the linker. In the 
work reported in this thesis, we investigated the SAR for cellular uptake and inhibitory activities 
of the 5-substituted pyrrolo[2,3-d]pyrimidine scaffold of 5, with variations in the length of the side 
chain and/or variations in the aromatic group in the side chain. The specific goal was to explore 
the SAR for novel 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 6-10 (Figure 9), related to 
the potent and FR selective 5-substituted pyrrolo[2,3-d]pyrimidines 4 and 5, for inhibiting the 
proliferation of FRα- and PCFT-expressing tumor cells with substantially reduced inhibitory 
effects toward normal RFC expressing cells.  
To validate our design effort, molecular modeling was conducted with published crystal 
structures. Both FRα and GARFTase, co-crystalized with pyrrolo[2,3-d]pyrimidines, have recently 
been reported by Gangjee and coworkers.89-90  The lead 5 and a representative proposed compound 
8 (Figure 9) were docked into the reported FRα and GARFTase crystal structures. For all the 
docking studies, Schrodinger Maestro 11.4 software package was used. This molecular modeling 
provided a molecular level interaction estimate of the receptors and ligands and allowed a 
determination of the rank order of bound conformations for each proposed molecule.  
Prior to docking 5 and 8, Maestro 11.4 was validated by re-docking the native ligands for 
reported GARFTase (AGF183) and FRα (AGF71) co-crystal structures. Figure 10A and 11A 
show the docked pose of 5 in the human FRα (PDB 5IZQ) binding site.89 Compound 5 binds in 
the same cleft of the co-crystalized ligand AGF183 (PDB 5IZQ). The 2-NH2 and N1 of 5, both 
interacts with Asp81 residue in the binding site. The 4-oxo forms hydrogen bonds with the side 
chain NH of Arg103. The pyrrolo[2,3-d]pyrimidine scaffold is sandwiched between the side chains 
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of Tyr85 and Trp171, similar to that seen with the pteroyl ring of AGF183 in its bound 
conformation. The L-glutamate moiety of 5 is oriented similarly to the corresponding glutamate in 
AGF183. The α-carboxylic acid of 5 forms a network of hydrogen bonds involving the backbone 
NH of Gly137 and Trp138 and the side chain NH of Trp140. The γ-carboxylic acid interacts with 
the side chain NH groups of Trp102, as is seen with the corresponding glutamate portion of 
AGF183 in the crystal structure. The hydrophobic 4C linker of 5 forms nonspecific hydrophobic 
interactions with Tyr60, Phe62, Trp102, and Trp134. The docking score of 5 is -14.46 kcal/mol. 
Compared to the docking for AGF183 of -13.23 kcal/mol, the docking score of 5 indicates a better 
binding. 
 
 
 
Figure 10. Molecular modeling studies of compounds 5 and 8 with FRα. (A) Docked pose of 5 
(magenta) in human FRα (PDB 5IZQ).89 (B) Docked pose of 8 (green) in human FRα (PDB 
5IZQ).89 
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Figure 11. (A) Ligand interaction map of 5 (magenta) in human FRα (PDB 5IZQ).89 (B) 
Ligand interaction map of 8 (green) in human FRα (PDB 5IZQ).89 
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The docked poses of 8 in human FRα retains the docking interactions of the pyrrolo[2,3-
d]pyrimidine scaffold and the thienoyl side chain, as seen with the docked pose of 5 (Figure 10B 
and 11B). The hydrogen bond between the 4-oxo and the side chain NH of Arg103 is also retained. 
There is an additional hydrogen bond between the N3 and Ser174. The α-COOH of glutamate 
chain of 8 maintains the network of hydrogen bonds with Trp138, Trp140 and Trp140 similar to 
that seen with the α-COOH of the glutamate chain of 5. The γ-COOH also retains the interaction 
with the side chain NH groups of Trp102. Unlike 5, a new pi-stacking interaction is observed 
between Trp102 and the furan ring of the side chain of 8. Similar to 5, the aliphatic side chain of 
8 occupies a hydrophobic pocket formed by Tyr60, Phe62, Trp102, and Trp134. The docking score 
of 8 was -13.30 kcal/mol, similar to AGF183, indicating strong potential of binding of 8 to FRα. 
  
 Figure 12. Molecular modeling studies of compounds 5 and 8 with GARFTase. (A) 
Docked pose of 5 (magenta) in GARFTase (PDB 4ZYV).90 (B) Docked pose of 8 (green) in 
GARFTase (PDB 4ZYV).90  
 Because 5 was identified as a GARFTase substrate in the in vitro protection studies on KB 
tumor cells, it was of interest to do comparative molecular modeling of 8 with 5 to identify its (8) 
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GARFTase inhibitory potential. Docking of 5 and 8 was conducted using the reported GARFTase 
crystal structure(PDB 4ZYV).90  
 
Figure 13. (A) Ligand interaction map of 5 (magenta) in GARFTase (PDB 4ZYV).90  
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Figure 13. (B) Ligand interaction map of 8 (green) in GARFTase (PDB 4ZYV).90 
 
Figure 12A and 13A show the docked pose of 5 in the GARFTase active site. Docked pose of 5 
was compared with the co-crystalized ligand AGF71 and a flip in the scaffold of 5 was observed 
compared to AGF71. The pyrrolo[2,3-d]pyrimidine scaffold of 5 shows interaction of the 2-NH2 
of 5 with the backbone of Leu899 and Glu948. The N3 of 5 forms a hydrogen bond with the 
backbone of Ala947, the N1 nitrogen forms a hydrogen bond with Leu899, and the 4-oxo moiety 
forms hydrogen bonds with the backbone atoms of Asp951. The pyrrole N7 nitrogen forms a 
hydrogen bond with the backbone of Arg897. The pyrrolo[2,3-d]pyrimidine scaffold of 5 forms 
hydrophobic interactions with Leu899, Val946, Ala947, Val950 and Ala952. The amide NH of 
the L-glutamate forms a hydrogen bond with Met896. The glutamate chain of 5 is oriented similar 
to the glutamate chain of co-crystalized ligand AGF71 with the α-COOH interacting with Arg871, 
and the γ-COOH interacting with Lys844 and a water molecule. The docking score of 5 in 
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GARFTase was −10.09 kcal/mol. Figure 12B and 13B show the docked pose of 8 in the GARFTase 
active site. The docked pose is similar to that of 5 in GARFTase described above. However, in 
case of 8, the γ-COOH of the glutamate flips and results in a loss of Lys844 and water interactions 
but replaces the α-COOH’s interactions with Arg871and Ile898. The docking score of 8 in 
GARFTase was -13.08 kcal/mol indicating a better binding than 5. 
 
Compounds 6, 7, 9 and 10 were docked in FRα and GARFTase in a similar fashion mentioned 
above. The docking score in FRα for 6 was -12.06 kcal/mol, for 7 was -13.46 kcal/mol, for 9 was 
-13.20 kcal/mol and for 10 was -13.73 kcal/mol.  The docking score in GARFTase for 6 was -9.84 
kcal/mol, for 7 was -11.87 kcal/mol, for 9 was -12.59 kcal/mol and for 10 was -12.86 kcal/mol. 
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IV. CHEMICAL DISCUSSION 
1. The synthesis of (S)-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamic acid 6. 
 Scheme 18. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 6. 
Reagents and conditions: (a) Pd(CH3COO)2, LiCH3COO, N(C4H9)4Cl, LiCl, 70 C,  4 h, 
68%; (b) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (c) 2,6-diamino-4-oxo-pyrimidine, CH3COONa, 
MeOH, 45 °C, 12 h, 51% over two steps; (d) (i). 1N NaOH, 45 C, 14 h; (ii). 1N HCl, 77%; (e) N-
Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, rt, 6 h, 98%; (f) (i). 1N NaOH, rt, 4 h; (ii). 1N HCl, 46%. 
 
Compound 6 (Scheme 18) was synthesized following a previously reported procedure.63 The key 
step in the scheme was the condensation of α-bromoaldehyde with 2,6-diamino-4-oxo-pyrimidine. 
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The first step was a Heck coupling reaction of aryl iodide 121 with commercially available 
unsaturated alcohol 120 in DMF at 70° C. This reaction afforded the aldehyde 122 (yield: 68%). 
As reported by Kanao et al.91, Bromine/1,4-dioxane dissolved in DCM was reacted with the 
aldehyde 122 at room temperature to yield α-bromoaldehyde compound 123, which was 
immediately used for the following step. Condensation of α-bromoaldehyde 123 with 2,6-diamino-
4-oxo-pyrimidine at 45 °C in the presence of sodium acetate afforded the 5-substituted pyrrolo[2,3-
d]pyrimidine 124 (yield 51% over two steps). Subsequent hydrolysis with 1N NaOH (yield: 77%), 
followed by coupling with diethyl L-glutamate using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents, afforded the diester 126 (yield: 98%). Final saponification 
of the diester with 1N NaOH afforded the final compound 6 (yield: 46%).  
2. The synthesis of (S)-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)furan-2-carbonyl)-L-glutamic acid 7. 
For the target compound 7 (Scheme 19), the side chain aryl group is a furan, instead of a phenyl 
in 6. For the synthesis of 7, a scheme similar to that used for 6 was employed with a slight 
modification. Unlike Scheme 18, where the starting material 121 was an ester, in Scheme 19  an 
acid (bromofuroic acid) was used as a starting material. Thus an extra step of hydrolyzing the ester 
to acid before glutamate coupling could be avoided and in Scheme 19 the glutamate coupling was 
conducted in the very first step.  With the starting material 5-bromo-2-furoic acid, diethyl L-
glutamate was reacted at room temperature using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents. This step produced the diester 128 (yield: 89%), which was 
subjected to Heck coupling. The diester 128 was reacted with commercially available unsaturated 
alcohol 129 in DMF at 70° C for 4 hours. This reaction afforded the aldehyde 130 (yield: 38%). 
The aldehyde 130 produced in this step proved difficult to isolate, and yield was substantially 
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lower than the same coupling step of Scheme 18. After isolating 130 via multiple CombiFlash 
column run (column chromatography), the intermediate was brominated. In the bromination step, 
bromine/1,4-dioxane dissolved in DCM was reacted with the aldehyde 130 at room temperature 
to yield the α-bromoaldehyde 131, which was immediately used for the next step.91 Condensation 
of α-bromoaldehyde 131 with 2,6-diamino-4-oxo-pyrimidine at 45 °C in the presence of sodium 
acetate afforded the 5-substituted pyrrolo[2,3-d]pyrimidine 132 (yield 12% over two steps). 
Subsequent saponification of the diester 132 with 1N NaOH afforded the final compound 7 (yield: 
45%).63 
 
 
Scheme 19. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 7. 
Reagents and conditions: (a) N-Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-
glutamate diethyl ester hydrochloride, DMF, rt, 12h, 89%; (b) Pd(CH3COO)2, LiCH3COO, 
N(C4H9)4Cl, LiCl, 129, DMF, 70 °C, 4 h, 38%; (c) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (d) 2,6-
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diaminopyrimidin-4(3H)-one, CH3COONa, MeOH, 45 °C, 12 h, 12% over two steps; (e) (i). 1N 
NaOH, rt, 2 h; (ii). 1N HCl, 45%. 
3. Alternative scheme for the synthesis of (S)-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-
pyrrolo[2,3-d]pyrimidin-5-yl)propyl)furan-2-carbonyl)-L-glutamic acid 7. 
 
 
 
Scheme 20. Alternative scheme for the synthesis of 2-amino-4-oxo-5-substituted-
pyrrolo[2,3-d]pyrimidine 7. 
Reagents and conditions: (a) CuI, PdCl2, PPh3, Et3N, CH3CN, pent-4-yn-1-ol, microwave, 100 °C, 
1 h, 58%; (b) 10% Pd/C, H2, 55 psi, MeOH, 12 h, 72%; (c) 1N NaOH, rt, 3 h; (ii). 1N HCl, 47%; 
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(d) N-Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, rt, 12h, 90%; (e) Dess-Martin Periodinane, CH2Cl2, 0 °C to rt, 3 h,74%, (f) 
Br2, 1,4-dioxane, CH2Cl2, rt, 3 h; (g) 2,6-diaminopyrimidin-4(3H)-one, CH3COONa, MeOH, 
45 °C, 12 h, 36% over two steps; (h) (i). 1N NaOH, rt, 3 h; (ii). 1N HCl, 34%. 
 In an effort to optimize the synthetic scheme and avoid the difficulty of separation in the 
Heck coupling step, an alternative coupling was employed to resynthesize target compound 7. 
Sonogashira coupling was tried and following the precedence in the literature, an ester was used 
as a starting material for this coupling reaction. In this scheme (Scheme 20), a modified microwave 
Sonogashira coupling reaction reported by Gangjee and coworkers92 was used as the first step. 
Compound 135 was obtained by a Sonogashira coupling of bromofuroate 133 with commercially 
available unsaturated alcohol 134 in a microwave reactor at 100 °C for 1 hour (yield: 58%). 
Compared to the Heck coupling step of Scheme 19, the yield of coupling product was significantly 
improved in Scheme 20 (58% yield in Sonogashira coupling vs. 38% yield in Heck coupling). 
Compound 135 was hydrogenated with 55 psi H2 in presence of catalyst palladium on carbon 
(yield: 72%) and subsequently hydrolyzed with 1N NaOH at room temperature to afford the acid 
137 (yield: 47%). Then 137 was reacted with L-glutamate diethyl ester hydrochloride in DMF to 
afford the diester 138 (yield: 90%) using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents. The alcohol portion of 138 was oxidized with Dess-Martin 
Periodinane to the aldehyde (yield: 74%) and then brominated at the α-position to yield 131. The 
α-bromoaldehyde 131 was immediately used in the next step for condensation with 2,6-diamino-
4-oxo-pyrimidine at 45 °C in the presence of sodium acetate to afford the 5-substituted pyrrolo[2,3-
d]pyrimidine 132 (yield 36% over two steps). Subsequent saponification of the diester 132 with 
1N NaOH afforded the final compound 7 (yield: 34%).63 
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4. The synthesis of (S)-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)furan-2-carbonyl)-L-glutamic acid 8. 
To optimize the Sonogashira coupling employed in Scheme 20, in Scheme 21, the coupling step 
was repeated several times for different durations. Repeating the Sonogashira coupling for 15 min, 
30 min and 60 min improved yield consistently but going beyond 60 min produced too many side 
products demonstrated by multiple spots in TLC. Yields for the three attempts were 27%, 63% and 
79% for 15 min, 30 min and 60 min respectively. The compound 140 obtained from these three 
reactions were mixed and subjected to the next reaction. Hydrogenation at 55 psi H2 in presence 
of catalyst palladium on carbon (yield: 85%) and subsequent oxidation with Dess-Martin 
Periodinane gave aldehyde 142 (yield: 84%). The aldehyde 142 was brominated to yield the α-
bromoaldehyde 143, which was immediately used in the next step to condense with 2,6-diamino-
4-oxo-pyrimidine at 45 °C in the presence of sodium acetate to afford the 5-substituted pyrrolo[2,3-
d]pyrimidine 144 (yield 46% over two steps). Unlike the previous scheme (Scheme 20), in Scheme 
21, glutamate coupling was performed at a later step to keep the molecular weight of the 
intermediates lower, so that the loss in each purification step remains low. Compound 144 was 
hydrolyzed with 1N NaOH at room temperature to afford the acid 145 (yield: 96%). Then 145 was 
activated with N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine and reacted with L-
glutamate diethyl ester hydrochloride in DMF to afford the diester 146 (yield: 43%). The diester 
146 was hydrolyzed with 1N NaOH and then precipitated by adding dropwise 1N HCl at 0 °C (till 
pH 3-4) to afford the final compound 8 (yield: 61%).63 
 51 
 
 
Scheme 21. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 8. 
Reagents and conditions. (a) CuI, PdCl2, PPh3, Et3N, CH3CN, 139, microwave, 100 °C, 15 min 
(26%) or, 30min (63%) or, 60min (78%); (b) 10% Pd/C, H2, 55 psi, MeOH, 12 h, 85%; (c) Dess-
Martin Periodinane, CH2Cl2, 0 °C to rt, 3 h, 84%, (d) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (e) 2,6-
diaminopyrimidin-4(3H)-one, CH3COONa, MeOH, 45 °C, 12 h, 46% over two steps; (f) 1N 
NaOH, rt, 3 h; (ii). 1N HCl, 96%; (g) N-Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-
triazine, L-glutamate diethyl ester hydrochloride, DMF, rt, 12h, 43%; (h) (i). 1N NaOH, rt, 3 h; 
(ii). 1N HCl, 61%. 
5. The synthesis of (S)-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)furan-2-carbonyl)-L-glutamic acid 9. 
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 Scheme 22. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 9. 
Reagents and conditions: (a) CuI, PdCl2, PPh3, Et3N, CH3CN, 147, microwave, 100 °C, 1 h, 57%; 
(b) 10% Pd/C, H2, 55 psi, MeOH, 12 h, 74%; (c) Dess-Martin Periodinane, CH2Cl2, 0 °C to rt, 3 
h, 71%, (d) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (e) 2,6-diaminopyrimidin-4(3H)-one, CH3COONa, 
MeOH, 45 °C, 12 h, 23% over two steps; (f) 1N NaOH, rt, 3 h; (ii). 1N HCl, 92%; (g) N-
Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, rt, 12 h, 98%; (h) (i). 1N NaOH, rt, 3 h; (ii). 1N HCl, 67%. 
The scheme for the synthesis of compound 8 was followed for the target compound 9 
(Scheme 22). In the first step of Scheme 21, as described above, the 60 min Sonogashira reaction 
provided best yield among the three options. Thus, this 60 min Sonogashira coupling was 
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performed with the unsaturated alcohol 147 and the bromofuroate 133 to afford 148 (yield: 57%).  
Hydrogenation of 148 with 55 psi H2 in presence of catalyst palladium on carbon, provided the 
saturated alcohol 149 (yield: 74%) which was then oxidized with Dess-Martin Periodinane to 
obtain aldehyde 150 (yield: 71%). The aldehyde 150 was brominated to yield the α-bromoaldehyde 
151, which was immediately used in the next step to condense with 2,6-diamino-4-oxo-pyrimidine 
at 45 °C to afford the 5-substituted pyrrolo[2,3-d]pyrimidine 152 (yield 23% over two steps). 
Compound 152 was hydrolyzed with 1N NaOH at room temperature to afford the acid 153 (yield: 
92%). Similar to Scheme 21, glutamate coupling was performed in step 7 of Scheme 22 to keep 
the molecular weight of the intermediates and as such, the loss in each purification step low. The 
5-substituted pyrrolo[2,3-d]pyrimidine 153 was activated as described in Scheme 21 and was 
coupled with L-glutamate diethyl ester hydrochloride in DMF to afford the diester 154 (yield: 
98%). The diester 154 was hydrolyzed with 1N NaOH and then precipitated by adding dropwise 
1N HCl at 0 °C (till pH 3-4) to afford the final compound 9 (yield: 67%).63 
 
6. The synthesis of (S)-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)-2-fluorobenzoyl)-L-glutamic acid 10. 
The scheme pursued for compound 8 and 9 (Scheme 21 and Scheme 22 respectively) 
provided relatively consistent yields in the critical Sonogashira coupling step (yield above 50% in 
both the schemes) and hence the scheme was adopted to synthesize target compound 10 (Scheme 
23). In the first step, a 60 minute Sonogashira coupling was performed between the 
bromofluorobenzoate 155 and the unsaturated alcohol 156 to afford 157 (yield: 63%).   
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 Scheme 23. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 10. 
Reagents and conditions(a) CuI, PdCl2, PPh3, Et3N, CH3CN, 156, microwave, 100 °C, 1 h, 63%; 
(b) 10% Pd/C, H2, 55 psi, MeOH, 9 h, 94%; (c) Dess-Martin Periodinane, CH2Cl2, 0 °C to rt, 3 h, 
44%, (d) Br2, 1,4-dioxane, CH2Cl2, rt, 3 h; (e) 2,6-diaminopyrimidin-4(3H)-one, CH3COONa, 
MeOH, 45 °C, 12 h, 45% over two steps; (f) 1N NaOH, rt, 3 h; (ii). 1N HCl, 95%; (g) N-
Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, rt, 12h, 58%; (h) (i). 1N NaOH, rt, 3 h; (ii). 1N HCl, 55%. 
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  Hydrogenation of 157 with catalyst palladium on carbon and 55 psi H2 provided the 
saturated alcohol 158 (yield: 94%) which was then oxidized with Dess-Martin Periodinane to 
obtain aldehyde 159 (yield: 44%). The aldehyde 159 was brominated to yield the α-bromoaldehyde 
160, which was immediately used in the next step to condense with 2,6-diamino-4-oxo-pyrimidine 
at 45 °C to afford the 5-substituted pyrrolo[2,3-d]pyrimidine 161 (yield: 45% over two steps). 
Compound 161 was hydrolyzed with 1N NaOH at room temperature to afford the acid 162 (yield: 
95%). Then 162 was activated with N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine and 
coupled with L-glutamate diethyl ester hydrochloride in DMF to afford the diester 163 (yield: 
58%). The diester 163 was hydrolyzed with 1N NaOH and then precipitated by adding dropwise 
1N HCl at 0 °C (till pH 3-4) to afford the final compound 10 (yield: 55%).63 
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V. SUMMARY 
In this study the design and synthesis of 5-substituted pyrrolo[2,3-d]pyrimidines as 
potential selective antifolate has been described. A total of five final compounds and thirty seven 
intermediates were synthesized as part of the study. Among the five final compounds, four were 
novel (6-9) and one (10) was previously reported. The previously reported compound was 
synthesized to explore previously unexplored FR/GARFTase selective biological activity. Four out 
of five final compounds were submitted for biological evaluation.  
Table 3: IC50s (in nM) for 5- substituted pyrrrolo[2,3-d]pyrimicline antifolates 6, 7, 8, 
10 and classical antifolates in RFC-, PCFT-, and FR-expressing cell lines 
Cmpd. Structure RFC FRα PCFT FRβ KB 
  
PC43-
10 
RT16 R2/hPCFT4 D4/FRβ KB 
6 5-pyrrole/4C/ 
1,2-phenyl 
>1000 >1000 >1000 >1000 >1000 
7 5-pyrrole/3C/ 
2,5-furan 
862 >1000 607.9 >1000 959.7 
8 5-pyrrole/4C/ 
2,5-furan 
>1000 196 >1000 >1000 709 
10 5-pyrrole/2C/ 
fluorophenyl 
169 6.8 26 8.9 73.4 
PMX 
(13) 
5-pyrrole/2C/ 
1,4-phenyl 
30.6 
(6.2) 
18.2(3.8) 22.3(8.6) - 9.94(3.11) 
MTX - 12(1.1) 114(31) 120.5(16.8) - 6.0(0.6) 
RTX - 6.3(1.3) 15(5) 99.5(11.4) - 5.9(2.2) 
LMTX - 12(2.3) 12(8) 38.0(5.3) - 1.2(0.6) 
 
Among the evaluated compounds, 6 totally lacked KB cell line inhibitory activity (IC50 > 
1000 nM). Compound 7, containing a 3C linker and a furan in the sidechain, had very little KB 
cell inhibitory activity (IC50 = 959.7 nM) resulting from limited RFC and PCFT transport. The 
compound demonstrated slight PCFT selectivity over RFC (PCFT IC50 = 607.9 nM and RFC IC50 
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= 862 nM). Increasing the chain length from 3C to 4C (compound 8) resulted in a dramatic change 
by totally eliminating the PCFT and RFC activity. However, 8 gained FRα (IC50 = 196 nM) 
selectivity over RFC (IC50 > 1000 nM). Replacement of sidechain furan with a fluorophenyl 
provided 10 which closely mimicked PMX; except for the presence of an extra fluorine atom on 
the sidechain aromatic group. Compared to other target compounds, 10 demonstrated better KB 
cell inhibition (IC50 = 73 nM) and good FRα and PCFT activity, but the FRα and PCFT selectivity 
over RFC was reduced (RFC IC50 = 169 nM, FRα IC50 = 6.8 nM and PCFT IC50 = 26 nM) 
compared to 8. However, 10 still demonstrated better FRα and PCFT selectivity over RFC than 
PMX (RFC IC50 = 30.6 nM, FRα IC50 = 18.2 nM and PCFT IC50 = 22.3 nM). 
The target compounds synthesized as part of this study are as follows: 
1. (S)-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamic acid (6) 
2. (S)-diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)furan-2-carbonyl)-L-glutamic acid (7) 
3. (S)-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)furan-2-carbonyl)-L-glutamic acid (8). 
4. (S)-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)furan-2-carbonyl)-L-glutamic acid (9) 
5. (S)-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)-2-fluorobenzoyl)-L-glutamic acid (10). 
Major intermediates synthesized as part of this study are as follows:  
1. 2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
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yl)butyl)benzoic acid (125) 
2. (S)-diethyl (2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamate (126) 
3. (S)-diethyl (5-(4-bromo-5-oxopentyl)furan-2-carbonyl)-L-glutamate (131). 
4. (S)-diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)furan-2-carbonyl)-L-glutamate (132) 
5.  (S)-diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)furan-2-carbonyl)-L-glutamate (146) 
6. 5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)furan-2-carboxylic acid (153) 
7. (S)-diethyl (5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)furan-2-carbonyl)-L-glutamate (154) 
8.  (S)-diethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)-2-fluorobenzoyl)-L-glutamate (163) 
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VI. EXPERIMENTAL 
 All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples 
were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P2O5 at 60 °C. Melting 
points were determined on a MEL-TEMP II melting point apparatus with FLUKE 51 K/J electronic 
thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (1H NMR) were 
recorded on Bruker Avance II 400 (400 MHz) and 500 (500 MHz) spectrometer. The chemical 
shift values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal 
standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Thin-layer 
chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates with a 
fluorescent indicator, and the spots were visualized under 254 and 366 nm illumination. 
Proportions of solvents used for TLC are by volume. Column chromatography was performed on 
CombiFlash Rf system (Teledyne ISCO, NE) with commercially available CombiFlash compatible 
12g, 24g or 40g silica columns (Teledyne ISCO, NE). The compounds were dry-packed on 
cartridge to use in the CombiFlash system. Packing was performed with either silica gel or celite 
of at least three times the weight of the crude. Elemental analyses were performed by Atlantic 
Microlab, Inc., Norcross, GA. Element compositions are determined with either one of the 
following softwares: Seareg (within ±0.4% of the calculated values), JASPER (not within ±0.4% 
of the calculated values). Fractional moles of water or organic solvents frequently found in some 
analytical samples of antifolates could not be prevented despite 24-48 h of drying in vacuo and 
were confirmed where possible by their presence in the 1H NMR spectra. All solvents and 
chemicals were purchased from Aldrich Chemical Co., Fisher Scientific and Matrix Scientific and 
were used as received. 
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Ethyl 2-(6-oxohexyl)benzoate (122). The alcohol hex-5-en-1-ol 120 (10.87 mmol, 1.09 g) was 
added to a solution of ethyl 2-iodobenzoate (121) (9.06 mmol, 2.5 g) in 30 mL of anhydrous DMF. 
Then LiCl (9.06 mmol, 383.90 mg), LiOAc  (22.64 mmol, 1.49 g), Bu4NCl (4.53 mmol, 1.26 g), 
and Pd(OAc)2 (543.34 mmol, 121.98 mg) was also added to the mixture, and the mixture was  
stirred at 70 °C for 4 h. TLC (hexane/EtOAc, 3:1) showed the disappearance of the starting material 
(Rf = 0.90) and formation of one major spot at Rf = 0.81. To the reaction mixture cooled to room 
temperature was add ethyl acetate (30 mL). The resulting solution was extracted with H2O (10 mL 
× 3) and dried over Na2SO4. After evaporation of solvent, the residue was loaded on a silica gel 
column (4 × 20 cm) and flash chromatographed with hexane/EtOAc, and the desired fractions (at 
3% EtOAc) were pooled. After evaporation of the solvent, the residue was dried in vacuo using 
P2O5 to afford 122 (1.54 g, yield 68%) as a colorless liquid, which was used directly for the next 
step without characterization. TLC Rf
  0.81 (hexane/EtOAc 3:1). 
Ethyl 2-(5-bromo-6-oxohexyl)benzoate (123). To 0.928 ml (10.85 mmol) dioxane, Br2 (0.317 
ml, 6.2 mmol) was added dropwise and the mixture was stirred for 10 min, and diluted with CH2Cl2 
(3.09 ml, 48.37 mmol). This solution was added dropwise to an ice-cool solution of 122 (1.54 g, 
6.20 mmol) in CH2Cl2 (3.09 ml, 48.37 mmol) over 3 h under N2. The mixture was stirred for 0.5 
h, then a solution of Na2CO3 in water (15 ml) was added. After being stirred for 1h, the reaction 
mixture was extracted with CHCl3 (15 ml). TLC was run and a new non polar spot was identified. 
The compound was unstable, so, it was immediately used for the cyclization reaction without 
characterization. 
Ethyl 2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoate 
(124). To a solution of 2,6-diamino-4-oxopyrimidine (860.66 mg, 6.82 mmol) and sodium acetate 
(1.02 g, 12.41 mmol) in water (15 mL) and methanol (15 mL) was added α-bromo aldehyde 123 
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(2.03 mg, 6.20 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.72 
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by 
silica gel (4 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel 
column (3.5 cm ×15 cm) and eluted by combiflash. Fractions showing Rf  = 0.72 (CHCl3/MeOH, 
5:1) were pooled and evaporated to afford 124 (1.12 g, yield 51% over two steps). TLC Rf
  0.72 
(CHCl3/MeOH, 5:1); 
1H NMR (400 MHz, DMSO-d6): δ 10.56 (s, 1H), 10.05 (s, 1H), 7.71-7.73 
(dd, J = 1.4, 7.8 Hz, 1H), 7.44-7.48 (td, J = 1.4, 7.7 Hz, 1H), 7.32-7.27 (m, 2H), 6.31-6.32 (d, J = 
2.1 Hz, 1H), 5.92 (s, 2H), 4.24-4.30 (q, J = 7.1 Hz, 2H), 2.83-2.92 (m, 2H), 2.56-2.60 (t, J = 7.4 
Hz, 2H), 1.51-1.65 (dq, J = 7.8, 35.9 Hz, 4H), 1.27-1.31 (t, J = 7.1 Hz, 3H). 
2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoic acid (125). 
To 124 (1.12 g, 3.16 mmol) in 30 mL of CH3OH was added 1 N NaOH (30 mL). The resulting 
mixture was stirred at 45 °C for 14 h. TLC indicated the disappearance of starting material and the 
formation of one major spot at Rf = 0.63 (CHCl3/MeOH 5:1). To this was added distilled water 
(10 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. 
The resulting suspension was chilled and thawed to 4 °C overnight in a refrigerator. The precipitate 
was filtered, washed with cold water, and dried in a desiccator under reduced pressure using P2O5 
(795 mg, 2.44 mmol) to afford 125 (0.79 g, yield 77%). Pale blue powder; MP > 180 °C 
(decomposed); TLC Rf = 0.63 (CHCl3/MeOH 5:1); 
1H NMR (DMSO-d6):  12.81 (s, 1H), 10.63 
(s, 1H), 10.16 (s, 1H), 7.73-7.75 (dd, 1H), 7.42-7.45 (td, 1H), 7.25-7.29 (m, 2H), 6.34-6.35 (d, 
1H), 6.02 (s, 2H), 2.89-2.93 (m, 2H), 2.55-2.58 (t, 2H), 1.53-1.61 (dq, 4H). Anal. calculated for 
(C17H18N4O3 · 0.8 H2O): C, 59.93; H, 5.79; N, 16.44; Found: C, 60.01; H, 5.60; N, 16.09. 
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(S)-diethyl(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamate (126). To a solution of 125, (500 mg, 1.53 mmol) in anhydrous 
DMF (20 mL) was added N-methylmopholine (0.2 mL, 1.8 mmol) and 2-chloro-4,6-dimethoxy-
1,3,5-triazine (322 mg, 1.8 mmol). The resulting mixture was stirred at room temperature for 2 h. 
To this mixture was added N-methylmopholine (0.2 mL, 1.8 mmol) and L-glutamic acid diethyl 
ester hydrochloride (473 mg, 2.3 mmol). The reaction mixture was stirred for an additional 4 h at 
room temperature and then evaporated to dryness under reduced pressure. The residue was mixed 
with 1 g of silica gel to make a plug and chromatographed with combiflash with 10% MeOH in 
CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were pooled and evaporated to 
dryness to afford 126 (769 mg, yield 98%). TLC Rf   0.84 (CHCl3/MeOH 5:1); compound was not 
characterized and was carried on to the next step. 
(S)-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoyl)-L-
glutamic acid (6). To a solution of the 126 (769 mg, 1.5 mmol) in MeOH (10 mL) was added 1N 
NaOH (10 mL) and the mixture was stirred at room temperature for 4 h. Then distilled water (5 
mL) was added, and the pH was adjusted to 3-4 by dropwise addition of 1N HCl. The resulting 
suspension was chilled and thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, 
washed with water and dried under vacuum with P2O5 to afford 6 (310 mg, yield 46%) as a dark 
blue powder. MP > 210 °C (decomposed); 1H NMR (DMSO-d6):   δ 12.42 (s, 2H), δ 10.61-10.62 
(d, 1H), 10.14 (s, 1H), 8.54-8.56 (d, 1H), 7.29-7.35 (m, 2H), 7.21-7.27 (m, 2H), 6.25-6.40 (d, 1H), 
5.97 (s, 2H), 4.34-4.40 (ddd, 1H), 2.69-2.74 (m, 1H), 2.54-2.57 (t, 2H), 2.36-2.40 (m, 2H), 1.82-
2.11 (m, 2H), 1.52-1.57 (m, 4H). Anal. calculated for (C22H25N5O6 · 0.65 H2O): C, 56.56; H, 5.67; 
N, 14.99; Found: C, 56.07; H, 5.53; N, 15.55. 
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(S)-diethyl (5-bromofuran-2-carbonyl)-L-glutamate (128): To do the peptide coupling,  acid 
127 (1 gm, 5.24 mmol) was taken in 50 mL DMF then  2-chloro-4,6-dimethoxy-1,3,5-triazine (1.1 
gm, 6.28 mmol) and N-methylmorpholine (635.55 mg, 6.28 mmol) were added. This was stirred 
in room temperature for 2 h. Then L-glutamate diethyl ester hydrochloride (1.62 gm, 7.96 mmol) 
and N-methylmorpholine (635.55 mg, 6.28 mmol) was added. This was stirred at room temperature 
for 12 hrs. TLC showed complete use of the starting material and formation of a major new spot 
at Rf = 0.58 (Hexane/EtOAc, 1:1). The reaction mixture was evaporated to dryness under reduced 
pressure. The residue was dissolved in MeOH, celite added and solvent evaporated to make a plug. 
From column run in combiflash, factions that showed the desired single spot at Rf = 0.58 were 
pooled and evaporated to dryness to afford 128 (1.75 gm, yield 89 %). TLC Rf 0.58 
(Hexane/EtOAc, 1:1); Viscous colorless liquid; 1H NMR (DMSO-d6):  δ 8.73-8.75 (d, J = 7.7 Hz, 
1H), 7.22-7.23 (d, J = 3.5 Hz, 1H), 6.78-6.79 (d, J = 3.5 Hz, 1H), 4.38-4.44 (ddd, J = 5.1, 7.6, 9.7 
Hz, 1H), 4.09-4.15 (qd, J = 1.4, 7.0 Hz, 2H), 4.02-4.07 (q, J = 7.1 Hz, 2H), 2.39-2.43 (t, J = 7.5 
Hz, 2H), 1.93-2.15 (m, 2H), 1.15-1.21 (dt, J = 7.1, 8.4 Hz, 6H). 
(S)-diethyl (5-(5-oxopentyl)furan-2-carbonyl)-L-glutamate (130): To a solution of 128 (3.85 
mmol, 1.45 mg) in 30 mL of anhydrous DMF were added pent-4-en-1-ol 129 (4.46 mmol, 400 
mg), LiCl (3.85 mmol, 163 mg), LiOAc  (9.66 mmol, 637 mg), Bu4NCl (1.95 mmol, 542 mg), and 
Pd(OAc)2 (0.232 mmol, 52 mg), and the mixture was  stirred at 70 
°C for 4 h. TLC  showed the 
disappearance of the starting material and formation of one major spot at Rf = 0.2 (hexane/EtOAc, 
1:1). To the reaction mixture, cooled to room temperature, was add ethyl acetate (30 mL). The 
resulting solution was extracted with H2O (10 mL × 3) and dried over Na2SO4. After evaporation 
of solvent, the residue was loaded on a silica gel column (4 × 20 cm) and flash chromatographed 
with hexane/EtOAc system, and the desired fractions (at 38% EtOAc) were pooled. After 
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evaporation of the solvent, the residue was dried in vacuo using P2O5 to afford 130 (672 mg, yield 
38%) as a light yellow liquid. TLC Rf  0.2 (hexane/EtOAc, 1:1); Light yellow liquid; 
1H NMR 
(400 MHz, Chloroform-d): δ 9.805-9.817 (t, J = 1.5 Hz, 1H), 7.05-7.06 (dd, J = 1.8, 3.4 Hz, 1H), 
6.92-6.94 (d, J = 8.1 Hz, 1H), 6.15-6.16 (d, J = 3.4 Hz, 1H), 4.77-4.82 (td, J = 5.0, 8.1 Hz, 1H), 
4.23-4.29 (qd, J = 2.7, 7.2 Hz, 2H), 4.08-4.18 (m, 2H), 2.68-2.77 (m, 2H), 2.37-2.66 (m, 4H), 2.04-
2.38 (m, 2H), 1.73-1.76 (q, J = 3.4 Hz, 4H), 1.31-1.35 (t, J = 7.1 Hz, 3H), 1.23-1.27 (t, J = 7.2 Hz, 
3H). 
(S)-diethyl (5-(5-oxopentyl)furan-2-carbonyl)-L-glutamate (130); Alternative scheme: 
Compound 138 (824 mg, 2.15 mmol) in anhydrous CH2Cl2 (5 mL) was added to a stirred solution 
of Dess-Martin periodinane (1.1 g, 2.59 mmol) in CH2Cl2 (5 mL) at 0 
°C, and then the mixture was 
allowed to warm to room temperature. Stirring was continued for 3 h. When the reaction was 
complete, excess oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous 
stirring, the mixture was diluted with ethyl acetate (10 mL), the organic layer was separated, and 
the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extracts were 
washed with brine, dried with MgS04, and concentrated to afford 130 (610 mg, yield 74%) as light 
yellow liquid.  1H NMR (400 MHz, Chloroform-d): δ 9.80-9.81 (t, J = 1.5 Hz, 1H), 7.05-7.06 (dd, 
J = 1.8, 3.4 Hz, 1H), 6.92-6.94 (d, J = 8.1 Hz, 1H), 6.15-6.16 (d, J = 3.4 Hz, 1H), 4.77-4.82 (td, J 
= 5.0, 8.1 Hz, 1H), 4.23-4.29 (qd, J = 2.7, 7.2 Hz, 2H), 4.08-4.18 (m, 2H), 2.68-2.77 (m, 2H), 2.37-
2.66 (m, 4H), 2.04-2.38 (m, 2H), 1.73-1.76 (q, J = 3.4 Hz, 4H), 1.31-1.35 (t, J = 7.1 Hz, 3H), 1.23-
1.27 (t, J = 7.2 Hz, 3H). 
(S)-diethyl (5-(4-bromo-5-oxopentyl)furan-2-carbonyl)-L-glutamate (131). To 1,4-dioxane 
(271  mg, 3.08 mmol) dissolved in CH2Cl2 (3 ml), Br2 (281 mg, 1.76 mmol) was added dropwise 
and the mixture was stirred for 10 min, and diluted with CH2Cl2 (3 ml). This solution was added 
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dropwise to an ice-cool solution of 130 (672 mg, 1.76 mmol) in CH2Cl2  (3 ml) over 3 h under N2. 
The mixture was stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After 
being stirred for 1h, the reaction mixture was extracted with CHCl3 (10 ml). TLC was run and a 
new non polar spot was identified. The compound was unstable, so, it was immediately used for 
the next step.  
(S)-diethyl(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)furan-
2-carbonyl)-L-glutamate (132). To a solution of 2,6-diamino-4-oxopyrimidine (244 mg, 1.94 
mmol) and sodium acetate (289 mg, 3.52 mmol) in water (10 mL) and methanol (10 mL) was 
added α-bromo aldehyde 131 (1.76 mmol) The reaction mixture was stirred at 45 °C for 12 h. TLC 
showed the disappearance of starting materials and the formation of one major spot at Rf = 0.48 
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by 
silica gel (4 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel 
column and eluted by combiflash. Fractions showing Rf = 0.48 were pooled and evaporated to 
afford 132 (99 mg, yield 12% over two steps) as a dark brown powder. MP 83 °C; TLC Rf
  0.48 
(CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6):   δ 10.68 (s, 1H), 10.12 (s, 1H), 8.47-8.49 (d, J = 7.7 
Hz, 1H), 7.07-7.08 (d, J = 3.3 Hz, 1H), 6.39-6.40 (d, J = 2.1 Hz, 1H), 6.33-6.44 (d, J = 3.4 Hz, 
1H), 6.00 (s, 2H), 4.36-4.42 (q, J = 7.8 Hz, 1H), 4.08-4.14 (m, 2H), 4.01-4.06 (q, J = 7.1 Hz, 2H), 
2.61-2.68 (dt, J = 7.4, 15.5 Hz, 4H), 2.38-2.41 (t, J = 7.4 Hz, 2H), 1.94-2.14 (m, 4H), 1.18-1.20 
(m, 3H), 1.14-1.17 (m, 3H). Anal. calculated for (C23H29N5O7 · 0.29 CHCl3): C, 53.52; H, 5.64; 
N, 13.39; Found: C, 53.58; H, 5.71; N, 13.21. 
(S)-diethyl(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)furan-
2-carbonyl)-L-glutamate (7). To 132 (99 mg, 203 mmol) in 10 mL of CH3OH was added 1 N 
NaOH (5 mL). The resulting mixture was stirred at room temperature for 2 hrs. TLC indicated the 
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disappearance of starting material and the formation of one major spot at Rf = 0.4 (CHCl3/MeOH, 
5:1 with 1 drop glacial acetic acid). To this was added distilled water (5 mL). The solution was 
cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The resulting suspension was 
thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, washed with cold water, 
and dried in a desiccator under reduced pressure using P2O5 to afford 7 (39 mg, yield 45%). 
Brownish white powder. MP > 153 °C (decomposed); TLC Rf
  0.4 (CHCl3/MeOH, 5:1 in acidic 
condition); 1H NMR (DMSO-d6):   δ 12.31 (s, 1H), 10.68 (s, 1H), 10.12 (s, 1H), 8.34-8.36 (d, J = 
7.9 Hz, 1H), 7.06-7.08 (d, J = 3.3 Hz, 1H), 6.40-6.42 (d, J = 2.1 Hz, 1H), 6.31-6.33 (d, J =3.4 Hz, 
1H), 6.00 (s, 2H), 4.31-4.38 (d, J = 9.9 Hz, 1H), 2.61-2.68 (dt, J = 7.5, 14.8 Hz, 4H), 2.30-2.34 (t, 
J = 7.6 Hz, 2H), 1.94-2.07 (dd, J = 8.2, 45.0 Hz, 4H). Anal. calculated for (C19H21N5O7 · 1 H2O): 
C, 50.75; H, 5.16; N, 15.57; Found: C, 50.76; H, 4.89; N, 15.46. 
Methyl 5-(5-hydroxypent-1-yn-1-yl)furan-2-carboxylate (135): To a 20-mL vial for microwave 
reaction, was added a mixture of palladium chloride (276.57 mg, 1.56 mmol), triphenylphosphine 
(409.10 mg, 1.56 mmol), triethylamine (400.19 mg, 9.75 mmol), methyl 5-bromofuran-2-
carboxylate, 133 (2 g, 9.75 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, were 
added copper(I) iodide (297.05 mg, 1.56 mmol), and pent-4-yn-1-ol, 134 (820 mg, 9.75 mmol), 
and the vial was sealed and put into the microwave reactor at 100 °C for 1 h. TLC showed a new 
spot between the two starting material. This reaction was repeated three times with same outcome, 
reaction mixtures were mixed and solvent evaporated. Then methanol and celite (10 g) was added 
and the solvent was evaporated under reduced pressure. The resulting plug was subjected flash 
chromatographed using combiflash machine in EtOAc/hexane system. The desired fraction (TLC) 
was collected and the solvent was evaporated under reduced pressure to afford 3.57 g (yield 58%) 
of 135 as orange brown powder. MP 53 °C; TLC Rf  0.45 (hexane/EtOAc 1:1); 1H NMR (400 MHz, 
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Chloroform-d):  7.15-7.16 (d, J = 3.5 Hz, 1H), 6.55-6.56 (d, J = 3.6 Hz, 1H), 3.92 (s, 3H), 3.80-
3.84 (q, J = 5.8 Hz, 2H), 2.59-2.62 (t, J = 7.0 Hz, 2H), 1.85-1.92 (m, 2H), 1.44-1.46 (t, J = 5.1 Hz, 
1H). Anal. calculated for (C11H12O4 · 0.17 H2O): C, 62.53; H, 5.88; Found: C, 62.52; H, 5.75. 
Methyl 5-(5-hydroxypentyl)furan-2-carboxylate (136): To a Parr flask was added 135 (1.5 g, 
7.2 mmol), 10% palladium on activated carbon (1.5 g), and MeOH (100 mL). Hydrogenation was 
carried out at 55 psi of H2 for 12 h. The reaction mixture was filtered through Celite, washed with 
MeOH (100 mL) and concentrated under reduced pressure to give 1.1 g (72%) of 136 as pale 
yellow semisolid. TLC Rf  0.48 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.11-
7.12 (d, J = 3.4 Hz, 1H), 6.14-6.15 (m, 1H), 3.89 (s, 3H), 3.65-3.68 (t, J = 6.5 Hz, 2H), 2.71-2.75 
(t, J = 7.5 Hz, 2H), 1.72-1.78 (m, 2H), 1.58-1.65(ddt, J = 6.2, 8.4, 9.8 Hz, 2H), 1.40-1.48 (m, 3H). 
5-(5-hydroxypentyl)furan-2-carboxylic acid (137). To 136 (1.1 g, 5.18 mmol) was added 1 N 
NaOH (5 mL). The resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the 
disappearance of starting material and the formation of one major spot at Rf  = 0.4 (CHCl3/MeOH, 
5:1). To this was added distilled water (5 mL). The solution was cooled in an ice bath, and the pH 
was adjusted 3 to 4 using 1 N HCl. The resulting suspension was thawed to 4 °C overnight in a 
refrigerator. The precipitate was filtered, washed with cold water, and dried in a desiccator under 
reduced pressure using P2O5 to afford 137 (484 mg, yield 47%). White powder. MP 55 °C; TLC 
Rf
  0.4 (CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6):   δ 7.25-7.26 (d, J = 3.5 Hz, 1H), 6.20-6.21 (d, 
J = 3.5 Hz, 1H), 3.67-3.70 (t, J = 6.5Hz, 2H), 2.74-2.78 (t, J = 7.6 Hz, 2H), 1.72-1.80 (m, 2H), 
1.60-1.67 (dq, J = 6.7, 8.7 Hz, 2H), 1.42-1.50 (m, 2H). Anal. calculated for (C10H14O4): C, 60.59; 
H, 7.11; Found: C, 60.50; H, 7.03. 
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(S)-diethyl (5-(5-hydroxypentyl)furan-2-carbonyl)-L-glutamate (138): In 50 mL DMF 137 
(475 mg, 2.40 mmol) was added. Then  2-chloro-4,6-dimethoxy-1,3,5-triazine (504.88 mg, 2.88 
mmol), N-methylmorpholine (605.97 mg, 5.99 mmol) and L-glutamate diethyl ester hydrochloride 
(730.54 mg, 3.59 mmol) were added in the stirred solution. This was stirred at room temperature 
for 12 hrs. TLC showed formation of a major new spot at Rf = 0.22 (Hexane/EtOAc, 1:1). The 
reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in 
MeOH, celite added and solvent evaporated to make a plug. From column run in combiflash 
(Hexane/EtOAc system), factions that showed the desired single spot at Rf  = 0.22 were pooled 
and evaporated to dryness to afford 138 (826 mg, yield 90%). Rf = 0.22 (Hexane/EtOAc, 1:1); 
Colorless liquid; 1H NMR (400 MHz, Chloroform-d):  δ 7.04-7.05 (d, J = 3.4 Hz, 1H), 6.95-6.97 
(d, J = 8.0 Hz, 1H), 6.12-6.13 (m, 1H), 4.77-4.82 (td, J = 4.9, 8.2 Hz, 1H), 4.21-4.29 (qd, J = 2.5, 
7.1 Hz, 2H), 4.09-4.15 (qd, J = 0.9, 7.1 Hz, 2H), 3.67-3.70 (t, J = 6.4 Hz, 2H), 2.69-2.73 (t, J = 7.5 
Hz, 2H), 2.38-2.54 (m, 2H), 2.06-2.37 (m, 2H), 1.68-1.77 (p, J = 7.6 Hz, 2H), 1.60-1.67 (m, 2H), 
1.44-1.52 (m, 2H), 1.30-1.34 (t, J = 7.1 Hz, 3H), 1.23-1.27 (t, J = 7.1 Hz, 3H). 
Methyl 5-(6-hydroxyhex-1-yn-1-yl)furan-2-carboxylate (140): To a 20-mL vial for microwave 
reaction, was added a mixture of palladium chloride (202.35 mg, 1.14 mmol), triphenylphosphine 
(299.32 mg, 1.14 mmol), triethylamine (7.22 g, 71.32 mmol), methyl 5-bromofuran-2-carboxylate, 
133 (1.46 g, 7.13 mmol) and anhydrous acetonitrile (8 mL). To the stirred mixture, were added 
copper(I) iodide (217.34 mg, 1.14 mmol), and hex-5-yn-1-ol, 139 (700 mg, 7.13 mmol), and the 
vial was sealed and put into the microwave reactor at 100 °C for 15 min. TLC showed a new spot 
with Rf  = 0.63 (hexane/EtOAc 1:1) between the two starting material. This reaction was repeated 
two more times for 30 min and 1 h respectively. For each reaction mixture solvent (acetonitrile) 
was evaporated. Then methanol and celite (4 g) was added and the solvent was evaporated under 
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reduced pressure. The resulting plug was subjected to flash chromatography using combiflash 
machine in EtOAc/hexane system. The desired fraction (TLC) was collected and the solvent was 
evaporated under reduced pressure to afford 140 as dark brown semisolid. Yield for 15 min, 30 
min, 1 h reactions were 26% (425 mg), 63% (1 g) and 79% (1.25 g) respectively. Dark brown 
semisolid; TLC Rf  0.63 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.15-7.16 (d, 
J = 3.5 Hz, 1H), 6.54-6.55 (d, J = 3.5 Hz, 1H), 3.91 (s, 3H), 3.71-3.74 (m, 2H), 2.50-2.53 (t, J = 
6.6 Hz, 1H), 1.68-1.79 (tdd, J = 2.6, 4.3, 7.1 Hz, 4H), 1.35 (s, 1H).  
Methyl 5-(6-hydroxyhexyl)furan-2-carboxylate (141): To a Parr flask was added 140 (2.67 g, 
11.70 mmol), 10% palladium on activated carbon (2 g), and MeOH (100 mL). Hydrogenation was 
carried out at 55 psi of H2 for 12 h. The reaction mixture was filtered through Celite, washed with 
MeOH (100 mL) and concentrated under reduced pressure to give 2.45 g (90%) of 141. Light 
brown liquid; TLC Rf  0.60 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.12-7.13 
(d, J = 3.3 Hz, 1H), 6.14-6.15 (m, 1H), 3.89-3.90 (d, J = 1.6 Hz, 3H), 3.64-3.68 (td, J = 1.3, 6.5 
Hz, 2H), 2.70-2.74 (t, J = 7.6 Hz, 2H), 1.68-1.76 (m, 2H), 1.59-1.61 (m, 2H), 1.38-1.43 (p, J = 3.6 
Hz, 4H). 
Methyl 5-(6-oxohexyl)furan-2-carboxylate (142): To a stirred solution of Dess-Martin 
periodinane (5.4 g, 12.73 mmol) in CH2Cl2 (8 mL), methyl 5-(6-hydroxyhexyl)furan-2-
carboxylate, 141 (2.4 g, 10.61 mmol) in anhydrous CH2Cl2 (8 mL) was added at 0 °C. Stirring was 
continued for 3 h and the mixture was allowed to warm to room temperature. When the reaction 
was complete, excess oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous 
stirring, the mixture was diluted with ethyl acetate (10 mL), the organic layer was separated, and 
the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extracts were 
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washed with brine, dried with MgS04, and concentrated to afford 142 (2 g, yield 84%). Pale yellow 
liquid.  1H NMR (400 MHz, Chloroform-d): δ 9.78-9.79 (t, J = 1.4 Hz, 1H), 7.11-7.13 (d, J = 3.4 
Hz, 1H), 6.14-6.15 (dd, J = 0.9, 3.3 Hz, 1H), 3.89-3.90 (d, J = 0.9 Hz, 3H), 2.70-2.74 (t, J = 7.6 
Hz, 2H), 2.45-2.49 (tt, J = 1.1, 7.4 Hz, 2H), 1.64-1.77 (dp, J = 7.5, 19.1 Hz, 4H), 1.37-1.44 (m, 
2H). 
Methyl 5-(5-bromo-6-oxohexyl)furan-2-carboxylate (143). To 1,4-dioxane (1.38 g, 15.61 
mmol) dissolved in CH2Cl2 (5 ml), Br2 (1.43 g, 456.8 mmol) was added dropwise and the mixture 
was stirred for 10 min, and diluted with CH2Cl2 (5 ml). This solution was added dropwise to an 
ice-cool solution of 142 (2 g, 8.92 mmol) in CH2Cl2 (5 ml) over 3 h under N2. The mixture was 
stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After being stirred for 1h, 
the reaction mixture was extracted with CHCl3 (2 x 10 ml). TLC was run and a new non polar spot 
was identified. The compound, 143, was unstable, so, it was immediately used for the next step. 
Methyl 5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-2-
carboxylate (144). To a solution of 2,6-diamino-4-oxopyrimidine (1.24 g, 9.8 mmol) and sodium 
acetate (4.46 g, 17.81 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde 
143 (8.91 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.56 
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by 
silica gel (10 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel 
column and eluted by combiflash. Fractions showing Rf = 0.56 were pooled and evaporated to 
afford 144 (1.43 g, yield 48% over two steps) as a dark brown powder. MP 149 °C; TLC Rf
   0.56 
(CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6):   δ 10.63 (s, 1H), 10.1 (s, 1H), 7.20-7.21 (d, 1H), 6.34-
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6.35 (d, 2H), 5.97 (s, 2H), 3.78 (s, 3H), 2.56-2.70 (m, 4H), 1.61-1.63 (m, 4H). Anal. calculated for 
(C16H18N4O4 · 1.65 CH3OH): C, 55.32; H, 6.47; N, 14.62; Found: C, 55.87; H, 5.69; N, 13.85. 
5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-2-carboxylic 
acid (145). To 144 (1 g, 3.03 mmol) was added 1 N NaOH (4 mL). The resulting mixture was 
stirred at room temperature for 3 hrs. TLC indicated the disappearance of starting material and the 
formation of one major spot at Rf  = 0.23 (CHCl3/MeOH, 5:1). To this was added distilled water 
(4 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The 
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, 
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 145 
(920 mg, yield 96%). Black semisolid; TLC Rf
  0.23 (CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6):   
δ 10.62-10.63 (d, J = 2.2 Hz, 1H), 10.18 (s, 1H), 7.02-7.03 (d, J = 3.4 Hz, 1H), 6.34-6.35 (d, J = 
2.0 Hz, 1H), 6.25-6.26 (d, J = 3.4 Hz, 1H), 6.01 (s, 2H), 2.57-2.67 (dt, J = 7.1, 29.1 Hz, 4H), 1.61-
1.63 (m, 4H). 
(S)-diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-
2-carbonyl)-L-glutamate (146): In 50 mL DMF, 145 (505 mg, 1.60 mmol) was added. Then 2-
chloro-4,6-dimethoxy-1,3,5-triazine (336.36 mg, 1.92 mmol), N-methylmorpholine (403.71 mg, 
3.99 mmol) and L-glutamate diethyl ester hydrochloride (493.19 mg, 2.43 mmol) were added in 
the stirred solution. This was stirred at room temperature for 12 hrs. TLC showed formation of a 
major new spot at Rf  = 0.59 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness 
under reduced pressure. The residue was dissolved in MeOH, celite added and solvent evaporated 
to make a plug. From column run in combiflash (CHCl3/MeOH), factions that showed the desired 
single spot at Rf  =  0.59 were pooled and evaporated to dryness to afford 146 (344 mg, yield 43%). 
Brown powder; MP > 143 °C (decomposed); TLC Rf
    0.59 (CHCl3/MeOH, 5:1); 1H NMR (400 
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MHz, DMSO-d6):  δ 10.63 (s, 1H), 10.11 (s, 1H), 8.47-8.49 (d, J = 7.6 Hz, 1H), 7.06-7.07 (d, J = 
3.3 Hz, 1H), 6.34-6.35 (d, J = 2.0 Hz, 1H), 6.26-6.27 (d, J = 3.4 Hz, 1H), 5.97 (s, 2H), 4.36-4.42 
(m, 1H), 4.09-4.13 (qd, J = 1.5, 7.2 Hz, 2H), 4.02-4.08 (q, J = 7.1 Hz, 2H), 2.58-2.67 (d, J = 32.1 
Hz, 4H), 2.38-2.42 (t, J = 7.5 Hz, 2H), 2.06-2.12 (p, J = 6.7, 7.4 Hz, 1H), 1.93-2.03 (m, 2H), 1.64-
1.66 (m, 4H), 1.15-1.20 (dt, J = 7.1, 9.0 Hz, 6H). Anal. calculated for (C24H31N5O7 · 1.25 H2O): 
C, 55.01; H, 6.44; N, 13.36; Found: C, 52.29; H, 5.82; N, 16.11. 
(S)-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-2-
carbonyl)-L-glutamic acid (8). To 146 (100 mg, 0.199 mmol) was added 1 N NaOH (2 mL). The 
resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the disappearance of 
starting material and the formation of one very polar major spot. To this was added distilled water 
(2 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The 
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, 
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 8 
(54 mg, yield 61%). Light green powder; TLC Rf
  0.2 (CHCl3/MeOH, 5:1 in acidic condition); 1H 
NMR (DMSO-d6):   δ 10.63 (s, 1H), 10.12 (s, 1H), 8.35-8.37 (d, J = 7.9 Hz, 1H), 7.05-7.06 (d, J 
= 3.4 Hz, 1H), 6.35-6.36 (d, J = 2.1 Hz, 1H), 6.26-6.27 (d, J = 3.3 Hz, 1H), 5.98 (s, 2H), 4.32-4.38 
(m, 1H), 2.65-2.70 (d, J = 4.5 Hz, 2H), 2.60 (s, 2H), 2.30-2.34 (t, J = 7.5 Hz, 2H), 1.87-2.10 (m, 
2H), 1.61-1.68 (m, 4H). Anal. calculated for (C20H23N5O7 · 0.88 H2O): C, 52.05; H, 5.41; N, 15.17; 
Found: C, 52.09; H, 5.34; N, 15.04. 
Methyl 5-(7-hydroxyhept-1-yn-1-yl)furan-2-carboxylate (148): To a 20-mL vial for microwave 
reaction, was added a mixture of palladium chloride (278.22 mg, 1.57 mmol), triphenylphosphine 
(411.54 mg, 1.57 mmol), triethylamine (9.92 g, 98.06 mmol), methyl 5-bromofuran-2-carboxylate, 
133 (2 g, 9.8 mmol) and anhydrous acetonitrile (7 mL). To the stirred mixture, were added 
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copper(I) iodide (298.82 mg, 1.57 mmol), and hept-6-yn-1-ol, 147 (1.1 g, 9.81 mmol), and the vial 
was sealed and put into the microwave reactor at 100 °C for 1 h. TLC showed a new spot with Rf 
=  0.35 (hexane/EtOAc 1:1) between the two starting material. This reaction was repeated one 
more time with similar outcome. Two reaction mixtures were mixed and solvent (acetonitrile) was 
evaporated. Then methanol and celite (12 g) was added and the solvent was evaporated under 
reduced pressure. The resulting plug was subjected to flash chromatography using combiflash 
machine in EtOAc/hexane system. The desired fraction (TLC) was collected and the solvent was 
evaporated under reduced pressure to afford 148 (3.99 g, yield 57%). Dark brown semisolid; TLC 
Rf  0.35 (hexane/EtOAc 1:1); 1H NMR (400 MHz, DMSO-d6): δ 7.33-7.34 (d, J = 3.6 Hz, 1H), 
6.86-6.87 (d, J = 3.7 Hz, 1H), 3.81 (s, 3H), 3.39-3.42 (t, J = 5.9 Hz, 2H), 1.52-1.59 (p, J = 7.0 Hz, 
4H), 1.38-1.48 (m, 4H). 
Methyl 5-(7-hydroxyheptyl)furan-2-carboxylate (149): To a Parr flask was added 148 (1.99 g, 
8.42 mmol), 10% palladium on activated carbon (2 g), and MeOH (100 mL). Hydrogenation was 
carried out at 55 psi of H2 for 18 h. The reaction mixture was filtered through Celite, washed with 
MeOH (100 mL) and concentrated under reduced pressure to give 1.5 g (74%) of 149. Light brown 
liquid; TLC Rf  0.53 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.11-7.13 (d, J = 
3.4 Hz, 1H), 6.13-6.15 (d, J = 3.3 Hz, 1H), 3.90 (s, 3H), 3.64-3.68 (t, J = 6.6 Hz, 2H), 2.69-2.73 
(t, J = 7.6 Hz, 2H), 1.67-1.74 (dd, J = 4.4, 10.2 Hz, 2H), 1.55-1.60 (q, J = 6.5 Hz, 2H), 1.35-1.39 
(d, J = 4.2 Hz, 6H), 1.31 (s, 1H). 
Methyl 5-(7-oxoheptyl)furan-2-carboxylate (150): To a stirred solution of Dess-Martin 
periodinane (3.18 g, 7.49 mmol) in CH2Cl2 (8 mL), methyl 5-(7-hydroxyheptyl)furan-2-
carboxylate, 149 (1.5 g, 6.24 mmol) in anhydrous CH2Cl2 (8 mL) was added at 0 °C. Stirring was 
continued for 3 h and the mixture was allowed to warm to room temperature. When the reaction 
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was complete, excess oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous 
stirring, the mixture was diluted with ethyl acetate (10 mL), the organic layer was separated, and 
the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extracts were 
washed with brine, dried with MgS04, and concentrated to afford 150 (1.05 g, yield 71%). Yellow 
liquid; TLC Rf  0.67 (hexane/EtOAc 1:1);  1H NMR (400 MHz, Chloroform-d): δ 9.78-9.79 (t, J = 
1.7 Hz, 1H), 7.11-7.13 (d, J = 3.4 Hz, 1H), 6.13-6.15 (m, 1H), 3.90 (s, 3H), 2.69-2.73 (t, J = 7.6 
Hz, 2H), 2.43-2.47 (td, J = 1.8, 7.3 Hz, 2H), 1.61-1.75 (m, 4H), 1.35-1.43 (m, 4H). 
Methyl 5-(6-bromo-7-oxoheptyl)furan-2-carboxylate (151). To 1,4-dioxane (679.42 mg, 7.71 
mmol) dissolved in CH2Cl2 (3ml), Br2 (704.20 mg, 225.7 mmol) was added dropwise and the 
mixture was stirred for 10 min, and diluted with CH2Cl2 (3 ml). This solution was added dropwise 
to an ice-cool solution of 150 (1.05 g, 4.41 mmol) in CH2Cl2 (5 ml) over 3 h under N2. The mixture 
was stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After being stirred for 
1h, the reaction mixture was extracted with CHCl3 (2 x 10 ml). TLC was run and a new non polar 
spot was identified. The compound, 151, was unstable, so, it was immediately used for the next 
step. 
Methyl 5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-2-
carboxylate (152). To a solution of 2,6-diamino-4-oxopyrimidine (1.1 g, 4.86 mmol) and sodium 
acetate (724.18 mg, 8.83 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo 
aldehyde 151 (4.41 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.65 
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by 
celite (4 g). Evaporation of the solvent afforded a plug, which was eluted by combiflash. Fractions 
showing Rf = 0.65 were pooled and evaporated to afford 152 (350 mg, yield 23% over two steps).  
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Orange brown powder. MP > 148 °C (decomposed); TLC Rf
   0.65 (CHCl3/MeOH, 5:1); 1H NMR 
(DMSO-d6):   δ 10.61 (s, 1H), 10.10 (s, 1H), 7.21-7.22 (d, J = 3.5 Hz, 1H), 6.34-6.35 (d, J = 3.5 
Hz, 1H), 6.32-6.33 (d, J = 2.0 Hz, 1H), 5.97 (s, 2H), 3.78 (s, 3H), 2.66-2.70 (t, J = 7.6 Hz, 2H), 
2.54-2.56 (d, J = 8.5 Hz, 2H), 1.57-1.66 (h, J = 7.5 Hz, 4H), 1.33-1.36 (q, J = 7.8 Hz, 2H). Anal. 
calculated for (C17H20N4O4 · 0.85 CH3OH): C, 57.69; H, 6.35; N, 15.08; Found: C, 58.17; H, 6.25; 
N, 14.62. 
5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-2-
carboxylic acid (153). To 152 (162 mg, 0.47 mmol) was added 1 N NaOH (3 mL). The resulting 
mixture was stirred at room temperature for 2 hrs. TLC indicated the disappearance of starting 
material and the formation of one major spot at Rf  = 0.33 (CHCl3/MeOH, 5:1). To this was added 
distilled water (3 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 
1 N HCl. The resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate 
was filtered, washed with cold water, and dried in a desiccator under reduced pressure using P2O5 
to afford 153 (143 mg, yield 92%). Pale yellowish white powder; TLC Rf
  0.33 (CHCl3/MeOH, 
5:1); 1H NMR (DMSO-d6):   δ 12.84 (s, 1H), 10.60-10.63 (d, J = 2.2 Hz, 1H), 10.12 (s, 1H), 7.10-
7.12 (d, J = 3.3 Hz, 1H), 6.33-6.34 (d, J = 2.0 Hz, 1H), 6.30-6.31 (d, J = 3.4 Hz, 1H), 5.99 (s, 2H), 
2.64-2.68 (t, J = 7.5 Hz, 2H), 2.54-2.56 (d, J = 7.5 Hz, 2H), 1.58-1.66 (qd, J = 3.7, 8.0 Hz, 4H), 
1.29-1.37 (h, J = 6.4, 7.3 Hz, 2H). Anal. calculated for (C16H18N4O4 · 0.62 CH3OH): C, 56.98; H, 
5.89; N, 15.98; Found: C, 57.07; H, 5.76; N, 15.83. 
(S)-diethyl(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-
2-carbonyl)-L-glutamate (154): In 20 mL DMF, 153 (101 mg, 0.305 mmol) was added. Then 2-
chloro-4,6-dimethoxy-1,3,5-triazine (64.42 mg, 0.366 mmol), N-methylmorpholine (77.31 mg, 
0.764 mmol) and L-glutamate diethyl ester hydrochloride (94.45 mg, 0.464 mmol) were added in 
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the stirred solution. This was stirred at room temperature for 12 hrs. TLC showed formation of a 
major new spot at Rf  = 0.66 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness 
under reduced pressure. The residue was dissolved in MeOH, celite added and solvent evaporated 
to make a plug. From column run in combiflash (CHCl3/MeOH), factions that showed the desired 
single spot at Rf  = 0.66 were pooled and evaporated to dryness to afford 154 (157 mg, yield 99%). 
Dark green powder; MP 110 °C; TLC Rf
   0.66 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-
d6):  δ 10.61 (s, 1H), 10.10 (s, 1H), 8.47-8.49 (d, J = 7.9 Hz, 1H), 7.06-7.07 (d, J = 3.5 Hz, 1H), 
6.34 (s, 1H), 6.27-6.29 (d, J = 3.4 Hz, 1H), 5.97 (s, 2H), 4.36-4.42 (q, J = 7.8 Hz, 1H), 4.08-4.13 
(q, J = 7.0 Hz, 2H), 4.01-4.07 (q, J = 7.0 Hz, 2H), 2.64-2.68 (t, J = 7.6 Hz, 2H), 2.53-2.56 (s, 2H), 
2.38-2.42 (t, J = 7.2 Hz, 2H), 1.95-2.12 (m, 2H), 1.59-1.67 (q, J = 8.3 Hz, 4H), 1.32-1.36 (m, 2H), 
1.14-1.20 (dt, J = 7.0, 10.0 Hz, 6H). Anal. calculated for (C25H33N5O7 · 0.9 H2O): C, 56.47; H, 
6.6; N, 13.17; Found: C, 55.27; H, 6.71; N, 14.43. 
(S)-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-2-
carbonyl)-L-glutamic acid (9). To 154 (75 mg, 0.145 mmol) was added 1 N NaOH (2 mL). The 
resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the disappearance of 
starting material and the formation of one very polar major spot. To this was added distilled water 
(2 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The 
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, 
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 9 
(45 mg, yield 67%). Pale greenish white powder; TLC Rf
  0.3 (CHCl3/MeOH, 5:1 in acidic 
condition); 1H NMR (DMSO-d6):   δ 12.53 (s, 2H), 10.68 (s, 1H), 10.25 (s, 1H), 8.34-8.36 (d, J = 
8.0 Hz, 1H), 7.06-7.07 (d, J = 3.4 Hz, 1H), 6.36-6.37 (d, J = 2.0 Hz, 1H), 6.26-6.27 (d, J = 3.3 Hz, 
1H), 6.14 (s, 2H), 4.32-4.38 (ddd, J = 4.8, 7.9, 9.9 Hz, 1H), 2.64-2.68 (d, J = 7.6 Hz, 2H), 2.53-
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2.57 (t, J = 7.7 Hz, 2H), 2.30-2.34 (t, J = 7.4 Hz, 2H), 1.89-2.12 (m, 2H), 1.59-1.69 (h, J = 8.1 Hz, 
4H), 1.33-1.38 (q, J = 7.7 Hz, 2H). Anal. calculated for (C21H25N5O7 · 0.21 CHCl3): C, 52.57; H, 
5.24; N, 14.45; Found: C, 52.58; H, 5.60; N, 14.32. 
Methyl 2-fluoro-4-(4-hydroxybut-1-yn-1-yl)benzoate (157): To a 20-mL vial for microwave 
reaction, was added a mixture of palladium chloride (182.15 mg, 1.03 mmol), triphenylphosphine 
(269.44 mg, 1.03 mmol), triethylamine (6.5 g, 64.20 mmol methyl 4-bromo-2-fluorobenzoate, 155 
(1.5 g, 6.42 mmol) and anhydrous acetonitrile (8 mL). To the stirred mixture, were added copper(I) 
iodide (195.64 mg, 1.03 mmol), and but-3-yn-1-ol, 156 (450 mg, 6.42 mmol), and the vial was 
sealed and put into the microwave reactor at 100 °C for 1 h. TLC showed a new spot with Rf = 
0.62 (hexane/EtOAc 1:1). This reaction was repeated two more time with similar outcome. Three 
reaction mixtures were mixed and solvent (acetonitrile) was evaporated. Then methanol and celite 
(10 g) was added and the solvent was evaporated under reduced pressure. The resulting plug was 
subjected to flash chromatography using combiflash machine in EtOAc/hexane system. The 
desired fraction (TLC) was collected and the solvent was evaporated under reduced pressure to 
afford 157 (2.7 g, yield 63%). Brown semisolid; TLC Rf   0.62 (hexane/EtOAc 1:1); 1H NMR (400 
MHz, Chloroform-d): δ 7.87-7.91 (t, J = 7.8 Hz, 1H), 7.17-7.26 (m, 2H), 3.95 (s, 3H), 3.84-3.88 
(q, J = 5.8 Hz, 2H), 2.72-2.75 (t, J = 6.3 Hz, 2H), 1.85-1.88 (t, J = 6.0 Hz, 1H). 
Methyl 2-fluoro-4-(4-hydroxybutyl)benzoate (158): To a Parr flask was added 157 (2 g, 9 
mmol), 10% palladium on activated carbon (2 g), and MeOH (100 mL). Hydrogenation was carried 
out at 55 psi of H2 for 9 h. The reaction mixture was filtered through Celite, washed with MeOH 
(100 mL) and concentrated under reduced pressure to give 1.93 g (95%) of 158. Colorless liquid; 
TLC Rf  0.56 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.85-7.88 (t, J = 7.8 Hz, 
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1H), 6.96-7.05 (m, 2H), 3.93 (s, 3H), 3.67-3.70 (t, J = 6.3 Hz, 2H), 2.68-2.72 (t, J = 7.6 Hz, 2H), 
1.58-1.78 (m, 4H), 1.43 (s, 1H). 
Methyl 2-fluoro-4-(4-oxobutyl)benzoate (159): To a stirred solution of Dess-Martin periodinane 
(4.34 g, 10.24 mmol) in CH2Cl2 (8 mL), methyl 2-fluoro-4-(4-hydroxybutyl)benzoate, 158 (1.93 
g, 8.53 mmol) in anhydrous CH2Cl2 (8 mL) was added at 0 °C. Stirring was continued for 3 h and 
the mixture was allowed to warm to room temperature. When the reaction was complete, excess 
oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous stirring, the mixture 
was diluted with ethyl acetate (10 mL), the organic layer was separated, and the aqueous layer was 
extracted with ethyl acetate (2 x 10 mL). The combined extracts were washed with brine, dried 
with MgS04, and concentrated to afford 159 (853 mg, yield 45%). Colorless liquid; TLC Rf  0.68 
(hexane/EtOAc 1:1);  1H NMR (400 MHz, Chloroform-d): δ 9.80-9.81 (t, J = 1.4 Hz, 1H), 7.87-
7.91 (t, J = 7.8 Hz, 1H), 6.97-7.05 (m, 2H), 3.94 (s, 3H), 2.69-2.73 (m, 2H), 2.49-2.53 (td, J = 1.4, 
7.3 Hz, 2H), 1.95-2.03 (p, J = 7.3 Hz, 2H). 
Methyl 4-(3-bromo-4-oxobutyl)-2-fluorobenzoate (160). To 1,4-dioxane (618.17 mg, 600.16 
mmol) dissolved in CH2Cl2 (3 ml), Br2 (640.71 mg, 205.36 mmol) was added dropwise and the 
mixture was stirred for 10 min, and diluted with CH2Cl2 (3 ml). This solution was added dropwise 
to an ice-cool solution of 159 (899 mg, 4.01 mmol) in CH2Cl2 (5 ml) over 3 h under N2. The 
mixture was stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After being 
stirred for 1h, the reaction mixture was extracted with CHCl3 (2 x 10 ml). TLC was run and a new 
non polar spot was identified. The compound, 160, was unstable, so, it was immediately used for 
the next step. 
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Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-
fluorobenzoate (161). To a solution of 2,6-diamino-4-oxopyrimidine (558.35 mg, 4.43 mmol) and 
sodium acetate (660.32 mg, 8.05 mmol) in water (10 mL) and methanol (10 mL) was added α-
bromo aldehyde 160 (4.02 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed 
the disappearance of starting materials and the formation of one major spot at Rf = 0.54 
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by 
celite (4 g). Evaporation of the solvent afforded a plug, which was eluted by combiflash 
(CHCl3/MeOH system). Fractions showing Rf = 0.54 were pooled and evaporated to afford 161 
(608 mg, yield 46% over two steps).  Pink powder; TLC Rf
   0.54 (CHCl3/MeOH, 5:1); 1H NMR 
(DMSO-d6):   10.65 (s, 1H), 10.19 (s, 1H), 7.77-7.81 (t, J = 8.0 Hz, 1H), 7.14-7.18 (m, 2H), 6.31-
6.33 (d, J = 2.1 Hz, 1H), 6.03 (s, 2H), 3.83 (s, 4H), 2.99-3.02 (dd, J = 6.3, 9.1 Hz, 2H), 2.84-2.88 
(dd, J = 6.2, 9.2 Hz, 2H). Anal. calculated for (C16H15FN4O3 · 0.46 H2O): C, 56.74; H, 4.74; N, 
16.54; F, 5.60; Found: C, 56.75; H, 4.55; N, 16.48; F, 5.48. 
4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-fluorobenzoic 
acid (162). To 161 (458 mg, 1.39 mmol) was added 1 N NaOH (3 mL). The resulting mixture was 
stirred at room temperature for 2 hrs. TLC indicated the disappearance of starting material and the 
formation of one major spot at Rf  = 0.45 (CHCl3/MeOH, 5:1). To this was added distilled water 
(3 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The 
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, 
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 162 
(420 mg, yield 96%). Light pink powder; MP > 274 °C (decomposed); TLC Rf
  0.45 
(CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6):   δ 10.65 (s, 1H), 10.19 (s, 1H), 7.74-7.78 (t, J = 7.9 
Hz, 1H), 7.11-7.13 (d, J = 9.8 Hz, 2H), 6.31-6.33 (d, J = 2.1 Hz, 1H), 6.04 (s, 2H), 2.97-3.01 (t, J 
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= 7.6 Hz, 2H), 2.84-2.88 (t, J = 7.7 Hz, 2H). Anal. calculated for (C15H13FN4O3 · 1 CH3OH): C, 
53.87; H, 4.52; N, 16.75; F, 5.68; Found: C, 53.97; H, 4.42; N, 16.47; F, 5.42. 
(S)-diethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-
fluorobenzoyl)-L-glutamate (163): In 20 mL DMF, 162 (300 mg, 0.948 mmol) was added. Then 
2-chloro-4,6-dimethoxy-1,3,5-triazine (199.83 mg, 1.14 mmol), N-methylmorpholine (239.85 mg, 
2.37 mmol) and L-glutamate diethyl ester hydrochloride (293.01 mg, 1.44 mmol) were added in 
the stirred solution. This was stirred at room temperature for 12 hrs. TLC showed formation of a 
major new spot at Rf  =  0.60 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness 
under reduced pressure. The residue was dissolved in MeOH, celite added and solvent evaporated 
to make a plug. From column run in combiflash (CHCl3/MeOH), factions that showed the desired 
single spot at Rf = 0.60 were pooled and evaporated to dryness to afford 163 (280 mg, yield 59%). 
Grey powder; MP > 228 °C (decomposed); TLC Rf
   0.60 (CHCl3/MeOH, 5:1); 1H NMR (400 
MHz, DMSO-d6):  δ 10.64 (d, J = 2.2 Hz, 1H), 10.17 (s, 1H), 8.57-8.59 (dd, J = 2.0, 7.5 Hz, 1H), 
7.47-7.51 (t, J = 7.7 Hz, 1H), 7.10-7.13 (m, 2H), 6.32-6.34 (d, J = 2.0 Hz, 1H), 6.06 (s, 2H), 4.38-
4.45 (ddd, J = 5.0, 7.4, 9.5 Hz, 1H), 4.08-4.15 (qd, J = 2.1, 7.2 Hz, 2H), 4.03-4.08 (q, J = 7.1 Hz, 
2H), 2.96-3.02 (dd, J = 6.1, 9.1 Hz, 2H), 2.83-2.88 (dd, J = 6.3, 9.1 Hz, 2H), 2.41-2.46 (td, J = 2.5, 
6.9, 7.4 Hz, 2H), 1.90-2.13 (m, J = 7.5, 13.1 Hz, 2H), 1.14-1.23 (dt, J = 7.1, 11.0 Hz, 6H). Anal. 
calculated for (C24H28FN5O6 · 1.4 H2O): C, 54.73; H, 5.89; N, 13.3; F, 3.61; found: C, 50.08; H, 
5.16; N, 18.02; F, 2.67. 
(S)-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-
fluorobenzoyl)-L-glutamic acid (10). To 163 (122 mg, 0.369 mmol) was added 1 N NaOH (2 
mL). The resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the 
disappearance of starting material and the formation of one very polar major spot. To this was 
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added distilled water (2 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 
4 using 1 N HCl. The resulting suspension was thawed to 4 °C overnight in a refrigerator. The 
precipitate was filtered, washed with cold water, and dried in a desiccator under reduced pressure 
using P2O5 to afford 10 (65 mg, yield 56%). Light green powder; TLC Rf
  0.22 (CHCl3/MeOH, 
5:1 in acidic condition); 1H NMR (DMSO-d6):   δ 10.64-10.65 (d, J = 2.3 Hz, 1H), 10.18 (s, 1H), 
8.42-8.44 (m, 1H), 7.50-7.54 (t, J = 7.7 Hz, 1H), 7.10-7.12 (d, J = 9.6 Hz, 2H), 6.32-6.34 (d, J = 
2.0 Hz, 1H), 6.04 (s, 2H), 4.39 (t, J = 11.1 Hz, 1H), 2.97-3.01 (dd, J = 6.0, 9.2 Hz, 2H), 2.84-2.88 
(m, 2H), 2.33-2.35 (d, J = 8.2 Hz, 2H), 1.91-2.09 (m, 2H). Anal. calculated for (C20H20FN5O6 · 
1.23 CH3OH): C, 52.59; H, 5.18; N, 14.44; F, 3.91; Found: C, 52.24; H, 4.95; N, 14.69; F, 3.85. 
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APPENDIX 
The biological evaluations of the analogs listed in the following tables were performed by 
Dr. Larry H. Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos Cancer 
Institute and the Cancer Biology Program and Department of Pharmacology, Wayne State 
University School of Medicine) against RFC-expressing PC43-10 cells, FRα-expressing RT16 
cells, FRβ-expressing D4 cells and hPCFT-expressing R2/hPCFT4 cells. The activities of PMX, 
MTX, RTX and LMTX were already reported in the literature. 
Cell Lines and Assays of Antitumor Drug Activities. RFC- and FRR-null 
MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne Flintoff (University of Western 
Ontario) and were cultured in R-minimal essential medium (MEM) supplemented with 10% 
bovine calf serum (Invitrogen, Carlsbad, CA), penicillin- streptomycin solution and L-glutamine 
at 37 °C with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC. RT16 cells are R2 cells 
transfected with human FRα, and D4 cells are R2 cells transfected with human FRβ. R2/hPCFT4 
cells were prepared by transfection of R2 cells with an hPCFT cDNA, epitope tagged at the C-
terminus with Myc-His6 (hPCFTMyc-His6) and cloned in pCDNA3.1. All the R2 transfected cells 
(PC43- 10, RT16, D4, R2/hPCFT4) were routinely cultured in R-MEM plus 1.5 mg/mL G418. 
Prior to the cytotoxicity assays, RT16 and D4 cells were cultured in complete folate-free 
RPMI1640 (without added folate) for 3 days. KB human cervical cancer cells were purchased from 
the American Type Culture Collection (Manassas, VA). Cells were routinely cultured in folate-
free RPMI1640 medium, supplemented with 10% fetal bovine serum, penicillin-streptomycin 
solution, and 2 mM L-glutamine at 37 °C with 5% CO2. For growth inhibition assays, cells (CHO 
or KB) were plated in 96 well dishes (∼2500-5000 cells/well, total volume of 200 µL medium) 
with a broad range of antifolate concentrations. The medium was RPMI1640 (contains 2.3 µM 
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folic acid) with 10% dialyzed serum and antibiotics for experiments with R2 and PC43-10 cells. 
For RT16, D4 and KB cells, the cells were cultured in folate-free RPMI media with 10% dialyzed 
fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 nM LCV. The requirement 
for FR mediated drug uptake in these assays was established in a parallel incubation including 200 
nM folic acid. For R2/hPCFT4 cells, the medium was folate-free RPMI1640 (pH 7.2) containing 
25 nM LCV, supplemented with 10% dialyzed fetal bovine serum (Invitrogen) and antibiotics. 
Cells were routinely incubated for up to 96 h, and metabolically active cells (a measure of cell 
viability) were assayed with Cell Titer-blue cell viability assay (Promega, Madison, WI), with 
fluorescence measured (590 nm emission, 560 nm excitation) using a fluorescence plate reader. 
Raw data were exported from Softmax Pro software to an Excel spreadsheet for analysis and 
determinations of IC50s, corresponding to the drug concentrations that result in 50% loss of cell 
growth. For assays of colony formation in the presence of the antifolate drugs, KB cells were 
harvested and diluted, and 200 cells were plated into 60 mm dishes in folate-free RPMI1640 
medium supplemented with 2 nM LCV, 10% dialyzed fetal bovine serum, penicillin-streptomycin, 
and 2 mM L-glutamine in the presence of antifolate drugs. The dishes were incubated at 37 °C 
with 5% CO2 for 10-14 days. At the end of the incubations, the dishes were rinsed with Dulbecco’s 
phosphate-buffered saline (DPBS), 5%trichloroacetic acid, and borate buffer (10 mM, pH 8.8), 
followed by 30 min incubation in 1% methylene blue in the borate buffer. The dishes were rinsed 
with the borate buffer, and colonies were counted for calculating percent colony-forming 
efficiency normalized to control.  
Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) CHO cells grown 
as monolayers were used to seed spinner flasks. For experiments to determine the inhibitions of 
transport by antifolate substrates, cells were collected and washed with DPBS and resuspended in 
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2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC43-10 cells and in HBS adjusted 
to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)-buffered saline (20 mM MES, 140 
mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) adjusted to pH 6.5, 6.0, or 5.5 for 
R2/hPCFT4 cells. In either case, uptakes of [3H]MTX (0.5 µM) were measured over 2 min at 37 
°C in the presence and absence of unlabeled antifolates (10 µM). Uptakes of [3H]MTX were 
quenched with ice-cold DPBS. Cells were washed with icecold DPBS (3×) and solubilized with 
0.5 N NaOH. Levels of intracellular radioactivity were expressed as pmol/mg protein, calculated 
from direct measurements of radioactivity and protein contents of cell homogenates. Protein 
concentrations were measured with Folin phenol reagent. Percent MTX transport inhibition was 
calculated by comparing level of [3H]MTX uptake in the presence and absence of the inhibitors. 
Kinetic constants (Kt, Vmax) and Kis were calculated from Lineweaver-Burke and Dixon plots, 
respectively. 
